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0. Summary 
 
The Hepatitis B virus (HBV) X protein (HBx) is essential for establishing natural 
viral infection and has been implicated in the development of liver cancer associated 
with chronic infection. The HBx protein has been reported to exhibit a variety of 
different activities in tissue culture cells, including induction of cell death and 
stimulation of HBV replication.  
In this work, we first show the functional importance of an interaction between HBx 
and the cellular protein DDB1 in HBx-mediated cell death. DDB1 is a protein 
originally described to form with DDB2 the UV-DDB complex that functions in DNA 
repair, and more recently found to assemble with cullin-4A and other proteins in 
complexes displaying E3 ubiquitin ligase activity. We provide evidence that HBx 
interferes with normal cell growth and viability by inducing lagging chromosomes 
and multinucleated cells. The mechanism whereby HBx causes cell cycle defects in 
association with DDB1 remains elusive. However, a comparative study between HBx 
and the unrelated V protein of the paramyxovirus simian virus 5, which also binds 
DDB1 and blocks interferon signaling by targeting STAT1 for proteolysis, raises the 
possibility that HBx may function through its interaction with DDB1 by targeting 
important cellular control proteins for degradation. 
We furthermore show that the HBx-DDB1 interaction is also critical for HBx to 
promote HBV genome replication in human hepatoma HepG2 cells. This stimulatory 
function of HBx shows the same requirements with respect to DDB1 binding than its 
previously reported effect on cell viability; it necessitates HBx and DDB1 to be 
interacting through their natural binding regions and to form a complex in the nuclear 
compartment of the cell. However, HBx retains DDB1-dependent cytotoxic properties 
but fails to promote HBV DNA replication in Huh-7 hepatoma cells, suggesting that 
the two activities are distinct. The finding that HBx performs both these activities 
when expressed at more physiological levels from its own viral genome rather than 
from a recombinant vector suggests that they are potentially relevant to HBV 
infection and/or associated liver carcinogenesis. 
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1. Résumé  
 
1.1 Introduction 
 
Le virus de l'hépatite B (VHB) est un des virus les plus importants du point de vue 
médical. L'Organisation Mondiale de la Santé (OMS) a estimé que près de 2 milliards 
d'individus ont été infectés par VHB sur la planète. La majorité des patients adultes 
surmontent l'infection. Cette dernière devient chronique lorsque le système 
immunitaire, qui normalement élimine le virus, est trop faible. Actuellement, plus de 
350 millions de personnes le sont de façon chronique, dont 25-40% vont mourir de 
cirrhose du foie ou de carcinome hépatocellulaire. Le virus se propage par contact 
sexuel, par les fluides corporels, notamment le sang, ou est transmis de la mère à 
l'enfant. L'infection néonatale explique le caractère endémique du VHB puisque la 
majorité de ces expositions résulte en une infection chronique due à une réponse 
immunitaire déficiente. VHB appartient à la famille des virus Hepadnaviridae (pour 
virus à ADN hépatotropique). Dans cette famille, on trouve d'autres virus animaux 
très bien caractérisés comme le WHV (woodchuck HV; marmotte), le GSHV (ground 
squirrel HV; écureuil) et le DHBV (duck HBV; canard). Les particules infectieuses 
sont constituées d'une enveloppe bi-lipidique externe enrobant une nucléocapside 
contenant l'ADN viral ainsi que la polymérase virale. Le génome viral d'une taille de 
3.2 kb se trouve sous une forme inhabituelle d'ADN circulaire partiellement double 
brin. Il présente une organisation hautement compacte et l'utilisation de cadres de 
lecture chevauchants. La particularité principale du cycle de multiplication du virus de 
l'hépatite B réside dans la réplication d'un génome ADN par rétro-transcription d'un 
intermédiaire ARN en dehors du noyau. L'entrée du virus dans la cellule et le 
cheminement du génome vers le noyau sont peu connus. Une fois dans le noyau le 
génome est maturé en ADN double brin circularisé de façon covalente (covalently 
closed circular; ccc) servant de matrice pour la transcription des ARN viraux par la 
polymérase de l'hôte. Un des transcrits dessert une double activité agissant soit 
comme messager permettant avec les autres transcrits la traduction des protéines 
virales, soit comme molécule d'ARN prégénomique. Cette dernière est encapsidée à 
l'intérieur des nucléocapsides se formant dans le cytosol et sert de matrice pour la 
 9
réplication du génome. Les différentes étapes d'expression  des protéines virales et de 
réplication du génome viral ont été intensément étudiées au contraire des étapes 
d'assemblage et de relâchement par les vésicules de sécrétion encore peu 
caractérisées. 
 
1.2 Contribution antérieure du laboratoire 
 
Le virus de l'hépatite B exprime une protéine accessoire de petite taille appelée X 
(HBx pour le virus humain), qui est bien conservée chez tous les hepadnavirus de 
mammifères. Cette protéine a été montrée être essentielle pour l'établissement de 
l'infection virale dans des modèles animaux de marmottes mais son mécanisme de 
stimulation de la réplication virale reste encore peu connu. De plus, bien que la 
protéine HBx n'ait pas de propriétés oncogéniques manifestes, des arguments indirects 
plaident en faveur d'un rôle de la protéine HBx dans la promotion des carcinomes 
hépatocellulaires. Néanmoins, le mode d'action de HBx dans les deux effets reste 
évasif et nécessite clairement de plus amples recherches permettant de déchiffrer les 
mécanismes moléculaires impliqués. Cette protéine multifonctionelle a été montrée 
interagir avec une multitude de protéines cellulaires et son expression dans des 
cellules en culture provoque de multiples effets agissant sur le contrôle du cycle 
cellulaire, la réparation de l'ADN, l'apoptose ou la croissance cellulaire.  
 
Notre laboratoire étudie le rôle de l'interaction entre HBx et DDB1 sur des cellules en 
culture et sur la réplication virale. DDB1 est la seule protéine ayant été montré 
interagir avec HBx par trois différents groupes, dont le nôtre, au moyen de criblage 
double-hybride dans la levure. DDB1 est une protéine ubiquiste et hautement 
conservée durant l'évolution, au contraire de son partenaire naturel DDB2 avec lequel 
il forme le complexe UV-DDB intervenant dans la réparation de l'ADN endommagé 
par UV. L'étude de l'interaction entre HBx et DDB1 permettra également de découvrir 
de nouveaux aspects de la biologie de cette protéine DDB1 gagnant en notoriété de 
jour en jour. 
 
La probable implication de HBx dans le développement de cancer du foie suggère que 
cette protéine puisse posséder des activités menant à la transformation de cellules en 
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culture. Nous n'avons obtenu aucune indication concernant un rôle éventuel de HBx 
dans la transformation de cellules (Publication 1). Au contraire, HBx empêche des 
oncogènes d'induire coopérativement des foci de cellules. L'expression de HBx 
provoque une altération de la morphologie suivie d'une mort cellulaire 5-7 jours après 
transfection et ceci aussi bien dans des cellules primaires que dans des cellules 
immortalisées.  
Au moyen d'un vaste criblage double-hybride dans la levure, Nathalie Lin-Marq, 
ancien membre du laboratoire, a isolé DDB1 comme molécule interagissant avec 
HBx. A l'aide de mutants de délétions, le domaine d'interaction avec DDB1 sur HBx a 
été restreint aux acides aminés 76 à 125 (Publication 1). Une analyse par mutations 
ciblées sur des résidus chargés de HBx permettant d'identifier les résidus impliqués 
dans l'interaction, a révélé une corrélation stricte entre la liaison avec DDB1 et les 
activités cytotoxiques. Les acides aminés en position 96 et 98 de HBx représentent 
deux sites cruciaux pour l'interaction avec DDB1. En effet, une mutation à l'une ou 
l'autre de ces deux positions abolit l'interaction entre DDB1 et HBx et par la même 
occasion l'activité cytotoxique. Ces connaissances à propos de l'interaction HBx-
DDB1 constituaient le point de départ de mon travail de thèse.  
 
1.3 HBx interfère avec la viabilité cellulaire par l'intermédiaire de son 
interaction avec DDB1   
 
Nous avons cherché des évidences prouvant que HBx exerce son effet sur la viabilité 
cellulaire par l'intermédiaire de son interaction avec DDB1 (Publication1). HBx ne 
semble pas fonctionner en séquestrant et empêchant DDB1 d'effectuer une fonction 
essentielle à la survie cellulaire. En effet, la surexpression de DDB1 ne permet pas de 
restaurer la viabilité des cellules exprimant HBx. Ce résultat suggère plutôt que HBx 
agit en conférant des activités inappropriées à DDB1.  Afin de tester cette hypothèse, 
le mutant HBx(R96E) qui est sévèrement compromis dans son interaction avec DDB1 
a été fusionné de façon directe avec sa cible cellulaire. La connexion entre ce mutant 
de HBx normalement inactif et DDB1, lui rend son activité. Ces expériences prouvent 
que le défaut du mutant est spécifiquement dû à son incapacité d'interagir 
efficacement avec DDB1. En conséquence, une interaction entre HBx et cette protéine 
DDB1 est cruciale pour l'activité cytotoxique induite par HBx.  
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 La majeure partie du travail a ensuite consisté à élucider les mécanismes moléculaires 
par lesquels HBx, au travers de son interaction avec DDB1, déclenche son activité 
antiproliférative. La distribution cellulaire de HBx étant toujours controversée, il est 
important de savoir dans quel compartiment cellulaire la protéine agit en collaboration 
avec DDB1. Séverine Bontron a pu montrer que HBx garde des activités cytotoxiques 
dépendantes de son interaction avec DDB1 lorsque manipulée de sorte à s'accumuler 
dans le noyau mais pas lorsque exclue du noyau. La fraction nucléaire de HBx est 
donc responsable de la mort cellulaire. Il a également été démontré que l'entrée de 
HBx dans le noyau s'effectuait indépendamment des deux sous-unités du complexe 
UV-DDB.  
 
Une autre protéine virale, SV5-V (Simian Virus 5 V protein), ainsi que des protéines 
similaires d'une famille de virus sans lien avec celle des hepadnavirus, a été montrée 
interagir avec DDB1. Le rôle de l'interaction entre DDB1 et SV5-V reste incertain. 
Une comparaison des propriétés de liaison à DDB1 entre HBx et SV5-V a été initiée 
dans le but d'élucider certains aspects du mécanisme menant à la perturbation de la 
viabilité cellulaire induite par HBx (Publication 2). Grâce à des expériences 
d'interaction protéine-protéine dans la levure, il a été possible de montrer que SV5-V 
et HBx liaient des domaines chevauchants sur DDB1. Par la suite des expériences de 
co-immunoprécipitations ont été effectuées afin d'observer l'effet de l'expression d'une 
des deux protéines virales sur la formation du complexe DDB1-DDB2. En effet, à ce 
moment là, toutes les activités connues de DDB1 nécessitaient l'interaction avec 
DDB2. Nos expériences montrent que SV5-V et HBx possèdent toutes les deux la 
capacité de perturber la formation du complexe UV-DDB et indiquent que la fonction 
médiée par leurs interactions respectives avec DDB1 peut s'effectuer en absence de 
DDB2. Des résultats précédents ont montré que la protéine HBx, possédant une courte 
demi-vie, est fortement stabilisée par son interaction physique avec DDB1. Nous 
avons donc testé si SV5-V s'accumulait aussi de façon DDB1-dépendante, en 
comparant les effets de la surexpression de DDB1 ou DDB2 sur le taux des protéines 
virales. De plus, l'effet sur la demi-vie des protéines virales après liaison à DDB1 a 
été observé au moyen d'expériences de pulse/chase. Nos résultats indiquent que les 
taux cellulaires de protéines HBx et SV5-V sont en partie déterminés par la 
stabilisation des protéines due à leur interaction avec DDB1. Connaissant les 
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nombreuses similarités entre HBx et SV5-V au niveau de l'interaction avec DDB1, 
nous avons testé si l'expression de SV5-V affectait la survie des cellules. SV5-V ne 
possède pas cette activité anti-proliférative, par contre SV5-V partage avec HBx et 
DDB2 la propriété d'induire l'accumulation de DDB1 endogène. Ces résultats 
suggèrent que la toxicité amorcée par HBx ne soit pas due à une accumulation 
nuisible de DDB1. Concordant avec ceci, les cellules surexprimant DDB1 en absence 
de HBx prolifèrent normalement. La toxicité induite par HBx n'est pas non plus due à 
sa capacité d'empêcher la formation du complexe UV-DDB, étant donné que SV5-V 
possède la même capacité tout en n'induisant pas de perturbation de la croissance 
cellulaire.  
La nature mutuellement exclusive de l'interaction entre DDB1 et les deux protéines 
virales, ainsi que le fait que SV5-V n'aie pas d'activité cytotoxique suggère que 
l'expression de SV5-V à des taux élevés permette d'empêcher HBx d'induire la mort 
cellulaire. En effet, nous avons montré que la surexpression de SV5-V relâche l'effet 
cytotoxique de HBx et le fait de façon plus efficace que DDB2.  Probablement, le 
compétiteur agit en déplaçant HBx de sa cible endogène DDB1 et empêche ainsi 
l'action néfaste sur la viabilité cellulaire. 
 
Nous avons ensuite voulu savoir si l'interaction fonctionnait selon un modèle "train ou 
pince". Selon le premier modèle, l'interaction entre HBx et DDB1 servirait 
uniquement de lien permettant aux deux protéines de se trouver ensemble à un endroit 
particulier de la cellule et la toxicité serait due à l'effet du cumul de deux activités 
indépendantes. La conformation pince impliquerait que les protéines doivent interagir 
pour former un complexe responsable de l'activité perturbatrice de la viabilité 
cellulaire. Afin de valider une de ces hypothèses, nous avons observé l'activité 
cytotoxique de fusions entre différentes versions de HBx et DDB1, ainsi que l'effet de 
la surexpression de SV5-V sur ces dernières. Les expériences démontrent que HBx et 
DDB1 doivent interagir au moyen de leurs sites d'interaction naturels et qu'une simple 
liaison covalente entre les deux n'est pas suffisante pour induire l'activité du 
complexe. Nous proposons donc que HBx réalise des activités nuisibles pour la 
cellule par l'intermédiaire de son interaction avec DDB1 et pour lesquelles SV5-V ne 
peut pas remplacer HBx.  
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Un autre aspect important est le décodage en termes moléculaires de la nature et de 
l'ordre des événements liant la formation du complexe HBx-DDB1 à l'induction de la 
mort cellulaire.  Le phénotype cellulaire induit par l'expression de HBx a dès lors été 
étudié de façon plus précise (Figure S2-3). Les cellules transfectées avec HBx 
présentent des défauts mitotiques tel que "chromosomes à la traîne", fuseaux 
mitotiques multiples résultant finalement en la formation de cellules multinuclées. 
L'analyse par cytométrie en flux de la quantité d'ADN  dans les cellules révèle 
l'apparition de cellules exprimant HBx avec un contenu en ADN supérieur à 4N et 
ceci de façon DDB1-dépendante. Le rôle de p53 (protéine impliquée dans de 
nombreux points de contrôle du cycle cellulaire) dans l'induction de la perturbation du 
cycle cellulaire a été étudié au moyen de lignées cellulaires différant dans leur statut 
de p53. Les défauts mitotiques sont observés aussi bien dans des cellules p53 
déficientes (Hep3B; HeLa dont  la protéine p53 est inhibée par une protéine virale) 
que dans des lignées p53 compétentes tel que HepG2. Ces dernières ont été soumises 
à une diminution de la quantité de p53 au moyen de la technique d'ARN interférence, 
puis le phénotype induit par différents mutants de HBx a été observé (Figure S4). 
Cette technique d'ARN interférence permet de diminuer de façon prolongée le taux de 
la protéine d'intérêt dans des cellules mammifères et d'observer l'effet de la déplétion 
sur les fonctions connues de la protéine. Ces expériences montrent que la perturbation 
de la viabilité cellulaire est induite par HBx de façon p53-indépendante mais par 
contre dépendante de son interaction avec DDB1.  
 
Nos résultats suggèrent que l'interaction entre HBx et DDB1 produit ou confère à 
DDB1 une nouvelle activité de façon indépendante de DDB2. La protéine DDB1, à 
l'encontre de DDB2, est hautement conservée à travers les espèces et est exprimée de 
manière ubiquiste. Dès lors, DDB1 joue probablement des rôles importants dans des 
fonctions cellulaires n'impliquant pas DDB2 encore à découvrir. Afin d'examiner les 
fonctions propres à DDB1, la technique d'ARN interférence a été utilisée. Nous avons 
dans un premier temps testé si DDB1 est impliquée dans l'activité de blocage de la 
voie de signalisation de l'interféron médiée par SV5-V (Publication 2). La protéine 
STAT1 est spécifiquement envoyée par SV5-V vers la dégradation par le système 
ubiquitine/protéasome. Cette activité anti-interféron permet au virus d'échapper au 
programme cellulaire de résistance contre les infections virales. La capacité de SV5-V  
à induire la dégradation de STAT1 est diminuée de 10 à 20 fois dans des cellules 
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exprimant des taux réduits de DDB1. DDB1 est donc essentiel pour la dégradation de 
STAT1 induite par SV5-V. La protéine HBx a également été testée pour des activités 
similaires, mais nous n'avons pas pu mettre en évidence une quelconque propriété 
inhibant la voie de signalisation de l'interféron.  
 
A long terme, la déplétion de DDB1 provoque une altération de la morphologie 
cellulaire ainsi qu'une perturbation de la viabilité cellulaire (Figure S8). Les 
aberrations phénotypiques observées, nécessitant de plus amples caractérisations, sont 
néanmoins semblables à celles récemment publiées pour la délétion du gène Ddb1 
dans la levure S.pombe. Dans cet organisme, DDB1 est impliqué dans la régulation du 
cycle cellulaire par l'intermédiaire de la dégradation d'une protéine régulant elle-
même d'autres protéines impliquées dans le contrôle de la réplication de l'ADN. La 
présence répétée de DDB1 dans des complexes de dégradation avec activité E3 
ubiquitine ligase est probablement due à son interaction avec la protéine cullin-4A 
responsable de cette activité. Ces faits suggèrent que HBx par l'intermédiaire de son 
interaction avec DDB1 puisse interférer avec la viabilité cellulaire en entraînant vers 
la protéolyse des protéines importantes pour le contrôle du cycle cellulaire. 
Des outils permettant une analyse structure/fonction de DDB1 ont été élaborés durant 
ce travail (Figure S9). En effet une version de DDB1 non-susceptible à l'ARN 
interférence (dû  à des mutations silencieuses dans la région de reconnaissance du 
siRNA) permet de complémenter les défauts, phénotypiques ou de dégradation de 
STAT1, observés suite à la déplétion de DDB1 par ARN interférence. Ceci représente 
également une démonstration de la spécificité du silencing contre DDB1. 
L'introduction de différentes mutations dans cette version non-susceptible de DDB1 
représente un moyen élégant de tester dans un environnement dépourvu de DDB1, les 
fonctions de différents mutants de cette protéine. Le rôle incombant à la protéine 
cullin-4A dans la toxicité induite par HBx ou dans la dégradation de STAT-1 par 
SV5-V pourra également être étudié au moyen d'outils d'ARN interférence ou de co-
immunoprécipitation élaborés durant ce travail (Figure S10). 
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 1.4 L'activité stimulatrice de HBx sur la réplication virale nécessite son 
interaction avec DDB1  
 
Nous avons démontré que l'interaction entre DDB1 et HBx est nécessaire pour 
l'activité cytotoxique de HBx en culture cellulaire. Le virus de l'hépatite B étant un 
virus non-cytopathique, il est peu probable que le rôle de sa protéine HBx lors de 
l'infection virale est de provoquer la mort des hépatocytes infectés. Le taux élevé de 
mort cellulaire observé dans le foie suite à l’infection par VHB est principalement dû 
à la réponse immunitaire de la cellule hôte. La présence de la protéine X du virus de la 
marmotte a été montrée être indispensable à la réplication virale. Nous avons donc 
voulu étudier la fonction de HBx dans la réplication virale et plus précisément le rôle 
de l'interaction entre HBx et DDB1 (Publication 3).  
A cet effet, nous avons procédé à des transfections de génomes VHB servant de 
matrice pour la transcription virale et permettant ainsi d'analyser les différentes étapes 
de la réplication virale. La régulation des transcrits se fait au moyen d'éléments virus-
spécifique et reflète ainsi une situation proche de l'infection virale. Tout 
particulièrement l'expression de HBx se fait dans le contexte général des autres 
protéines virales et correspond probablement au faible taux observé lors de l'infection 
virale. Les différents intermédiaires de la réplication du virus VHB contenus dans les 
capsides virales sont isolés et analysés par la technique de Southern Blot. Dans la 
lignée hépatique HepG2, la réplication virale est fortement altérée lorsque l'expression 
de la protéine HBx du génome est inhibée par insertion d'un codon stop dans son 
cadre de lecture. La capacité de complémentation du défaut de réplication du génome 
dépourvu de HBx a été testé pour différents mutants de HBx. Nous avons montré que 
l'expression d'une version sauvage de HBx, au contraire d'une version HBx(R96E) 
compromise dans son interaction avec DDB1, permet de restaurer le taux altéré de 
réplication virale obtenu par un génome dépourvu de HBx. Au moyen d'une série de 
mutants de la protéine virale HBx nous avons pu démontrer une corrélation entre 
liaison avec DDB1 et stimulation de la réplication virale. De plus la formation d'une 
liaison covalente entre DDB1 et le mutant HBx(R96E), permet à ce dernier de 
retrouver une activité promotrice de la réplication virale. Ces résultats montrent que la 
stimulation de la réplication de VHB induite par HBx, corrèle avec la formation du 
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complexe DDB1-HBx et nécessite l'interaction des deux protéines par l'intermédiaire 
de leurs sites naturels de liaison. Afin de directement tester le rôle de DDB1 dans 
l'activité promotrice de la réplication virale médiée par HBx, la technique de l'ARN 
interférence ciblée contre DDB1 et délivrée au moyen de transduction virale a été 
utilisée. Le taux de réplication du VHB sauvage est considérablement réduit dans des 
cellules déplétées en DDB1 alors que la réplication du VHB déficient en HBx n'est 
pas affectée. Cette expérience montre que DDB1 est essentiel pour permettre à HBx 
de stimuler la réplication virale. La protéine HBx étant localisée aussi bien dans le 
noyau que dans le cytoplasme, nous avons voulu déterminer quelle fraction 
subcellulaire de HBx était responsable de l'effet sur la réplication virale. En utilisant 
des versions de HBx à localisation strictement restreinte au noyau ou au cytoplasme, 
nous avons pu montrer que la fraction nucléaire de HBx manifestait cette activité 
promotrice de la réplication. Consistant avec une activité nucléaire de HBx, nous 
avons observé une réduction marquée de la quantité des transcrits viraux en l'absence 
de la protéine virale HBx. L'interaction entre HBx et DDB1 est nécessaire pour 
l'obtention d'un taux approprié de  transcrits viraux comme en témoigne l'absence 
d'augmentation de ce taux en présence du mutant HBx(R96E) spécifiquement 
compromis dans sa liaison avec DDB1. Ces expériences démontrent la nécessité pour 
HBx d'interagir avec DDB1 afin de permettre une réplication virale optimale. 
A ce point, nos études montrent des exigences similaires relatives à l'interaction avec 
DDB1 pour les deux effets dépendants de HBx étudiés ici : perturbation de la viabilité 
cellulaire et stimulation de la réplication virale. Or des études dans une autre lignée 
hépatique (Huh7) suggèrent que l'effet de HBx sur la viabilité cellulaire ne soit pas lié 
à l'effet stimulateur sur la réplication virale. En effet, l'expression de HBx induit une 
toxicité de façon DDB1-dépendante dans les deux lignées hépatiques. Par contre, la 
réplication virale est dépendante de HBx uniquement dans la lignée HepG2 mais pas 
dans la lignée Huh7. Ces résultats nous permettent de proposer que les deux activités 
induites par HBx suivent des chemins différents après l'interaction initiale entre 
DDB1 et HBx. 
 
Afin de découvrir les événements ultérieurs à la formation du complexe entre HBx et 
DDB1 et dans le but d'isoler des protéines interagissant avec ce complexe, un criblage 
"double hybride plus" a été effectué (Figure S13). En utilisant DDB1 comme appât, 
en présence ou absence de HBx, cette expérience permet d'isoler des protéines 
 17
interagissant non seulement avec le complexe mais également avec DDB1 seul. De la 
sorte, nous avons pu isoler une protéine hTRP4-AP, interagissant avec DDB1 et dont 
la liaison est possible en présence ou absence de HBx. SV5-V par contre empêche 
l'interaction entre DDB1 et hTRP4-AP suggérant que l'étude de cette interaction 
mérite un approfondissement. Des études supplémentaires au moyen de techniques tel 
que co-immunoprécipitation et ARN interférence sont nécessaires afin de confirmer 
cette interaction dans des cellules mammifères et d'analyser son effet sur les 
différentes fonctions de DDB1. 
 
1.5 Conclusion 
 
En conclusion, les résultats présentés dans cette thèse apportent de précieux éléments 
en ce qui concerne le mécanisme et la fonction de l'interaction entre HBx et une de 
ses cibles cellulaires DDB1. Nous avons approfondi nos connaissances sur l'activité 
cytotoxique induite par HBx dans des cellules en culture. De façon plus importante 
sur le plan médical, nous avons pu démontrer que cette interaction joue également un 
rôle primordial pour la réplication du virus de l'hépatite B. Ces résultats permettent 
d'envisager le développement de nouvelles molécules anti-virales ciblant l'interaction 
entre HBx et DDB1. 
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2. Introduction 
 
2.1 Hepatitis B Virus Biology 
2.1.1 Introduction 
 
Hepatitis B virus (HBV) has been estimated by the World Health Organization 
(WHO) to have infected over two billion people worldwide. Approximately 350 
million people are chronically infected with HBV, and overwhelming epidemiological 
evidence indicates that they are at high risk for the development of liver diseases 
including cirrhosis and hepatocellular carcinoma (HCC) [1-3]. HBV-associated HCC 
is one of the most common cancers in humans causing about 1 million deaths yearly 
[4]. Although an effective HBV vaccine has been available for nearly 20 years [5], 
vaccination is not a treatment for established infections. On the other hand, current 
attempts at treatment of chronic HBV infections, such as alpha interferon and 
lamivudine therapy, have had only limited success [6]. Thus, the development of fully 
effective treatment strategies for chronic infection by HBV remains a major 
challenge. 
McCallum, first introduced the terms, hepatitis A and hepatitis B, in 1947 in order to 
categorize infectious (epidemic) and serum hepatitis (homologous serum jaundice). 
The chain of events that culminated in the discovery of the virus and an effective 
vaccine for the prevention of hepatitis B was not straightforward. In 1963, when 
searching for polymorphic serum proteins, Blumberg discovered a previously 
unknown protein in the blood of an Australian aborigine. This protein was denoted as 
the Australia (Au) antigen. By 1968, other investigators had established that the Au 
antigen (now known as the hepatitis B surface antigen, HBs) was only found in the 
serum of type B hepatitis infected patients [7; 8]. The discovery and characterization 
of HBs was a major breakthrough in hepatitis B research because it permitted 
intensive study of the disease and of the nature of the infectious agent even though the 
virus itself had not yet been identified conclusively. In the early seventies, Dane 
detected the complete hepatitis B virion, a 42-nm double-shelled particle that 
consisted of an outer envelope composed of HBs [9]. The inner core or nucleocapsid 
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contained the hepatitis B core antigen (HBc or C protein) in addition to a small, 
circular, double-stranded DNA molecule and the viral DNA polymerase enzyme (P 
protein) [10; 11].  
The HBV genome is unique in the world of viruses due to its compact nature, use of 
overlapping reading frames, and dependence on a reverse-transcriptional step, though 
the virion contains primarily DNA. In light of this, the human hepatitis B virus 
became the archetype of a family of viruses called Hepadnaviridae (for hepatotropic 
DNA viruses). Those most closely related to HBV have been found in woodchucks 
and ground squirrels. These viruses have about 70% sequence homology to HBV but 
are not known to infect human or other primates; in contrast HBV is infectious for the 
great apes. The viruses infecting mammals are grouped (due to DNA sequence and 
genome organization similarities) in the genus Orthohepadnavirus. More distantly 
related ducks and geese hepatitis viruses are grouped in the Avihepadnavirus genus.  
There are seven major HBV genotypes (A to G) prevailing in different parts of the 
world: A is pandemic, B and C are found in Asia, D in southern Europe, E in Africa, 
F in America and G in the USA and France. Another newly discovered HBV 
genotype H has been found in Central America. These genotypes are mainly used for 
epidemiological reasons, however some HBV genotypes may affect disease profiles 
and responses to treatment differentially. There are four serotypes that are based on 
subtypes of the hepatitis B surface antigen. Two mutually exclusive determinants 
pairs d/y and w/r with a common determinant 'a' define these subtypes called adw, 
ayw, adr and ayr. 
 
2.1.2 Epidemiology and pathogenesis 
 
HBV is a ubiquitous organism that is globally distributed among humans (reviewed in 
[12; 13]). Though HBs has been found in other primates, humans remain the principal 
reservoir. Serological surveys have documented the existence of hepatitis B 
throughout the world, including the most isolate and remote areas (Figure 1). The 
prevalence of HBV has been decreasing in developed countries, thanks to the 
availability of the hepatitis B vaccine, increasing knowledge of how the virus is 
spread as well as screening of donated blood before use. 
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Figure 1: Global distribution of Hepatitis B virus, prevalence rate of HBs antigen in 
the world [13] 
 
Transmission of HBV is primarily through blood but the virus has also been detected 
in a variety of other bodily fluids including semen, urine, saliva/nasopharyngeal fluids 
and menstrual fluids [14; 15]. Airborne and feces infections have not been 
incriminated as a source of infection [16]. HBV can survive even on a dry surface for 
a week yet remain infectious [17], therefore uninfected individuals living with an 
HBV carrier are statistically at greater risk of contracting HBV than those not living 
with a carrier. Maternal-neonatal transmission of HBV has largely been documented. 
The rate of infection varies among ethnic groups, in different parts of the world and in 
different periods of pregnancy. This way of transmission may represent the most 
important mechanism for maintenance of an HBV carrier population in certain areas 
of the world. Actually, chronic infection begins when the immune response that 
normally clears the infection is too weak to be effective (see below). Therefore 
infected newborns having an immature immune system, almost always, become 
chronic carriers. The large HBV reservoir is responsible for the maintenance of its 
satellite virus: the Hepatitis delta virus (HDV). 
In endemic areas of Asia and Africa, the epidemiological patterns of infection are 
different from those seen in North America and Western Europe. Most infections in 
these developing regions occur in infants or early childhood contact, whereas sexual 
activity and percutaneous exposure are the main risk factors in western countries. 
 
The primary site of HBV replication is the liver. The liver plays an essential role in 
energy storage and conversion, blood homeostasis, chemical detoxification, and 
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immunity of microbial infections. Although the liver is composed of many different 
types of cells, much of the functional activity resides in hepatocytes (which constitute 
70% of the liver), bile duct epithelium, and Kupffer cells (macrophages). Hepatocytes 
are the only confirmed site of replication for all members of this liver-tropic virus 
family. Bile ductule epithelial cells may also be targets of infection, as may a subset 
of cells in the pancreas, kidneys and lymphoid system. However, the evidence of 
replication in bile ducts and extrahepatic sites are controversial in mammalian 
members of the family. Hepatocytes and bile ductule epithelial cells are liver-specific 
and may be replaced by extensive proliferation, or proliferation/differentiation of a 
common progenitor cell, in response to very acute forms of liver injury. Indeed, the 
liver is the only organ able to regenerate itself even following partial hepatectomy of 
70% of the liver. Thus while hepatocytes may represent a fairly homogenous 
population of quiescent cells at the time of infection, the situation can rapidly change 
as the immune system attacks infected cells (see below). A recent report estimated the 
hepatocyte turnover during resolution of a transient hepadnaviral infection to a 
minimum of 0.7 to 1, suggesting that a large fraction of the infected hepatocyte 
population was killed and replaced by hepatocyte cell division [18]. This means that 
an understanding of HBV infections requires an understanding of how the liver 
regenerates, as well as how components of the virus replication machinery including 
transcriptionally active viral DNAs, behave as the infected cells begin to divide 
(reviewed in [3]). 
 
The hepatitis B virus (HBV) is mostly not directly cytopathic to the cells. It appears 
that the intense levels of cell death are primarily due to host defense mechanisms 
against HBV infection. The tissue damages are of variable severity ranging from 
acute hepatitis (including fulminant hepatitis, 1% of the infections) to chronic 
infection, cirrhosis and hepatocellular carcinoma. Most primary infections in adults, 
whether symptomatic or nor, are self-limited, with clearance of virus from blood and 
liver and the development of lasting immunity to reinfection. However some primary 
infections in healthy adults (generally less than 5 percent) do not resolve but develop 
into persistent infections. Chronically infected patients may only develop light 
pathologies and therefore represent the major epidemiological reservoir because they 
are poorly aware of their infectious potential. These people have an increased risk of 
HCC development 25-30 years after infection. While HBV-related HCC may develop 
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in the absence of cirrhosis or extensive liver damage, the appearance of HCC in 
patients with chronic hepatitis C virus (HCV) infection is usually preceded by the 
establishment of significant liver damage [4]. The diversity of clinical syndromes and 
disease manifestations associated with HBV infection strongly suggests that the 
clinical outcome of this infection is determined by the quality and vigor of the 
antiviral immune response produced by the infected host (reviewed in [19-21]) .  
The immune responses to HBV and their role in the pathogenesis of hepatitis B are 
incompletely understood. Correlative clinical studies show that in acute, self-limited 
hepatitis B, strong T-cell responses to many HBV antigens are readily demonstrable 
in the peripheral blood. These responses involve both major-histocompatibility-
complex (MHC) class II–restricted, CD4+ helper T cells and MHC class I–restricted, 
CD8+ cytotoxic T lymphocytes. The antiviral cytotoxic T-lymphocyte response is 
directed against multiple epitopes within the HBV core, polymerase, and envelope 
proteins; strong helper T-cell responses to core and polymerase proteins have also 
been demonstrated in acute infection. By contrast, in chronic carriers of HBV, such 
virus-specific T-cell responses are greatly attenuated, at least as assayed in cells from 
the peripheral blood. However, antibody responses are vigorous and sustained in both 
situations. This pattern strongly suggests that T-cell responses, especially the 
responses of cytotoxic T lymphocytes, play a central role in viral clearance. The 
number of hepatocytes killed by direct engagement between cytotoxic T lymphocytes 
and their targets is very small and clearly insufficient to account for most of the liver 
damage. This suggests that much of the injury is due to secondary antigen-nonspecific 
inflammatory responses that are set in motion by the response of the cytotoxic T 
lymphocytes. Presumably, much of the damage occurring in this context is due to 
cytotoxic by-products of the inflammatory response, such as tumor necrosis factor 
(TNF), free radicals, and proteases. Other immune-cell populations, notably natural 
killer T cells, probably also contribute to liver injury. 
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Figure 2: Cellular Immune Responses to HBV 
HBV replicates in hepatocytes to produce HBs particles and virions. Both types of particle can be taken 
up by antigen-presenting cells, which degrade the viral proteins to peptides that are then presented on 
the cell surface bound to MHC class I or II molecules. (Antigen-presenting cells can also process and 
display viral antigens taken up by phagocytosis of killed infected hepatocytes.) These peptide antigens 
can be recognized by CD8+ or CD4+ T cells, respectively, which are thereby sensitized. Virus-specific 
CD8+ cytotoxic T cells (with help from CD4+ T cells, green arrow) can recognize viral antigens 
presented on MHC class I chains on infected hepatocytes. This recognition reaction can lead to either 
direct lysis of the infected hepatocyte or the release of interferon-γ and TNF-α, which can down-
regulate viral replication in surrounding hepatocytes without direct cell killing. [22] 
 
Destruction of infected cells, however, is not the only mechanism implicated in the 
elimination of intracellular virus, as demonstrated by studies carried out in animal 
models of HBV infection showing the importance of cytokine-mediated (IFN-γ and 
TNF-α), non-cytolytic mechanisms of anti-viral protection. This is supported by the 
observation that control of viral replication and elimination of most HBV-DNA 
molecules occur before onset of liver damage and clinical symptoms. All limbs of the 
immune response must cooperate productively to terminate a viral infection (Figure 
2). Individual differences in the efficiency of viral antigen processing by hepatocytes 
and professional antigen-presenting cells, or at the level of antigen recognition and 
responsiveness by B and T lymphocytes, will affect the strength of the antiviral 
immune response and the extent to which it contributes to viral clearance and liver 
disease. Finally, chronic hepatitis appears to be due to a suboptimal cellular immune 
response that destroys some of the infected hepatocytes and does not purge the virus 
from the remaining infected hepatocytes, thereby permitting the persisting virus to 
trigger a chronic indolent necroinflammatory liver disease that sets the stage for 
development of HCC. The different frequencies of chronic infection development 
 24
between adults (<5%) and new-borns (80-90%) suggest that the efficiency of the 
immune response to the primary infection is critical for the disease outcome. Viral 
variants (due to high frequency of errors of the viral polymerase) and the HBe antigen 
(blood-secreted antigen probably acting as HBV tolerogen in case of in utero 
exposition) are also suggested to be involved in chronicity due to their influence on 
the efficiency of the immune response. 
 
The two modes of treatment for hepatitis B (reviewed in [23; 24]) are 
immunomodulation (IFN-α) and viral suppression (nucleoside analogues that target 
the viral-encoded reverse transcriptase, inhibiting its activity and terminating viral 
DNA chain extension). Administration of IFN-α shows in about 30% of the patients a 
successful response with decline of viral markers, however the treatment is 
contraindicated for advanced liver diseases and the side effects are numerous. 
Lamivudine (also called 3TC) is the first nucleoside analogue to be licensed for 
treatment of chronic hepatitis. Viral load is rapidly decreased by 3 to 4 logs upon 
lamivudine treatment with minor side effects. The major drawback of lamivudine 
therapy is the emergence of resistant HBV variants with mutation in the catalytic 
domain of the polymerase. The use of adefovir (second approved nucleoside 
analogue) is more efficient for viral load decrease and until now no resistant viruses 
have been described.  New nucleoside analogues as well as combination therapy are 
currently in clinical trials. 
 
2.1.3 Virion and genome structure 
 
Virion structure  
HBV-infected cells produce three types of viral particles: 40-47-nm double-shelled 
particles called Dane particles, 20-nm spheres, and small quantities of filaments of 20-
nm diameter and variable length. All three have a common antigen on their surface, 
termed hepatitis B surface antigen. HBs are present in enormous quantity in the serum 
of infected hosts allowing the physician to use direct antigen detection as a sensitive 
diagnostic test for HBV infection. Most of the circulating pool of HBs is composed of 
20-nm spheres (that outnumbers Dane virions by 10,000:1 to 1 Mio: 1). 
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Figure 3: The structure of the hepatitis B virus virion 
The outer envelope of the virion contains three related glycoproteins (L, M and S); the inner 
nucleocapsid contains a single capsid protein (C). The viral DNA contains a terminal polymerase 
protein (P) attached to the negative strand. 
 
The Dane particle is the infectious virion of HBV (Figure 3). The external lipoprotein 
envelope can be removed by treatment with nonionic detergents, liberating an inner 
core particle or nucleocapsid of 25 to 27 nm. The major structural protein of the core 
is the C protein. Within the core are the viral DNA and a polymerase activity known 
to be involved in viral genomic replication. 
The 20-nm spheres and filaments lack nucleic acid and hence are noninfectious. 
Nonetheless, in pure form, these particles are highly immunogenic and served as the 
initial form of HBV vaccine before development of recombinant HBs preparations. 
 
Viral genome 
HBV virion DNA is a relaxed circular, partially duplex species of 3.2 kb whose 
circularity is maintained by 5'-cohesive ends [25-27]. The negative strand is unit 
length and has the polymerase protein covalently linked to its 5' end. By contrast, the 
positive strand is less than unit length and bears a capped oligoribonucleotide at its 5' 
end. Importantly, the positions of the 5' ends of both strands map to the regions of 
short direct repeat (DRs), which are involved in priming the synthesis of their 
respective DNA strands. Virion DNA thus contains a single-stranded region or gap of 
fixed polarity but variable length. The HBV DNA is highly compacted: every 
nucleotide in the genome is within a coding region, and more than half of the 
sequence is translated in more than one frame. In addition the genome also contains 
genetic elements which regulate levels of transcription, determine the site of 
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polyadenylation and even mark a specific transcript for encapsidation into the 
nucleocapsid (reviewed in [13; 28]). 
There are four defined overlapping open reading frames (ORFs) in the HBV genome 
(Figure 4). The use of varying in-frame start codons result in the expression of seven 
different hepatitis B proteins. The preS–S (presurface–surface) region of the genome 
encodes the three viral surface antigens by initiation of translation at three in-frame 
initiation codons. The most abundant protein is the 24-kD S protein (known as HBs), 
which is the major constituent of the 20-nm empty particles. Initiation at the middle 
start codon generates the 31-kD M (or preS2) protein, the function of which is 
unknown. Initiation at the most upstream initiation codon yields the 39-kD L (or 
preS1) protein. Dane infectious particles are substantially enriched for L chains. 
Because L chains are thought to carry the receptor recognition domain, this 
enrichment may prevent the more numerous 20-nm particles from competing 
effectively with virions for cell surface receptors. 
 
 
Figure 4: Schematic representation of the hepatitis B virus coding organization 
Left: Diagrammatic representation of the hepatitis B virus coding organization. Inner circle represents 
virion DNA, with dashes showing the single-stranded genomic region; the locations of DR1 and DR2 
sequence elements are indicated. Boxes denote viral coding regions, with arrows indicating direction of 
translation. Outermost wavy lines depict the viral RNAs identified in infected cells, with arrows 
indicating direction of transcription.  
Right: Fine structure of the 5´ ends of the pre-C/C transcripts (top) and pre-S2/S transcripts (bottom) 
relative to their respective open reading frames. 
 
 
The preC–C (precore–core) region encodes hepatitis B core antigen (HBc) and 
hepatitis B early antigen (HBe). These two proteins are also derived by alternative 
initiation of translation at two in-frame AUG codons. The internal AUG encodes the 
21-kD C protein, the structural polypeptide of the viral nucleocapsid, whereas the 
upstream AUG directs production of the 24-kD preC protein. The preC region 
 27
encodes a signal sequence, which directs the chain into the secretory pathway. As the 
chains traverse the Golgi complex, cleavage by cellular proteases generates HBe, a 
16-kD fragment that is secreted into the blood.  
The P coding region encompassing the majority of the genome, encodes the viral 
polymerase, a multifunctional enzyme involved in DNA synthesis and RNA 
encapsidation.  
Last but not least, the X open reading frame encodes the 17-kD X protein (HBx), 
which modulates host-cell signal transduction and can directly and indirectly affects 
host and viral gene expression. HBx protein activity is required for the viral 
replication in vivo and spread of the virus but how it does so is still mysterious. 
Chapter 2.2 will allow to get insights into the world of the multifunctional HBx 
protein. The aim of this thesis was to gain a better understanding of the mechanisms 
governing the different effects of HBx on the host cell and their possible implications 
for viral HBV replication. 
  
2.1.4 Viral life cycle 
 
Overview 
The main features of the life cycle of the hepadnaviruses are shown in Figure 5 and 
reviewed in [13; 22; 28]. The major curiosity discovered by Summers and Mason in 
1982 [29] is the replication of the DNA genome by reverse transcription of an RNA 
intermediate outside of the nucleus.  
Incoming HBV virions are bound by cell-surface receptors, the identity of which 
remains unknown. After membrane fusion, cores are presented to the cytosol and 
translocated to the nucleus. There, their genomic DNA is maturated to a covalently 
closed circular (ccc) form, which serves as a transcriptional template for host RNA 
polymerase II. The cccDNA molecules play in the HBV life cycle the role analogous 
to that of integrated proviral DNA in retroviral replication. The resulting RNAs are 
transported to the cytoplasm where they are translated to give rise to the viral 
envelope, core, X and polymerase proteins. Next, nucleocapsids are assembled in the 
cytosol, and during this process a single molecule of pregenomic RNA is incorporated 
together with the polymerase into the assembling viral core. Within this structure, 
viral DNA synthesis is sequentially initiated: after negative-stranded synthesis and 
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concomitant degradation of the RNA template, positive-stranded DNA synthesis 
occurs. 
 
 
 
Figure 5: The Replication Cycle of HBV 
HBV virions bind to surface receptors and are internalized. Viral core particles migrate to the 
hepatocyte nucleus, where their genomes are repaired to form a covalently closed circular DNA 
(cccDNA) that is the template for viral messenger RNA (mRNA) transcription. The resulting viral 
mRNAs translated in the cytoplasm to produce the viral surface, core, polymerase, and X proteins. 
There, progeny viral capsids assemble, incorporating genomic viral RNA (RNA packaging). This RNA 
is reverse-transcribed into viral DNA. The resulting cores can either bud into the endoplasmic 
reticulum to be enveloped and exported from the cell or recycle their genomes into the nucleus for 
conversion to cccDNA. The small, peach-colored sphere inside the core particle is the viral DNA 
polymerase. [22] 
 
Some cores bearing the newly synthesized genome are recycled back to the nucleus to 
maintain a stable intranuclear pool of transcriptional templates. However, most cores 
bud into intracellular membranes (endoplasmic reticulum or proximal Golgi) to 
acquire their glycoprotein envelope containing the viral surface antigens. Enveloped 
virions are then secreted through the constitutive pathway of vesicular transport. 
 
Binding and Entry 
Several lines of evidences suggest that the early steps of virus-cell attachment and 
entry determine the viral tropism and susceptibility (reviewed in [30; 31]). The 
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analysis of the life cycle of the human HBV, especially the initial steps of attachment 
and entry, is hampered mainly by the lack of cell lines that are susceptible to HBV 
infection. The recently available HepaRG human cell line supporting HBV infection 
will be described in chapter 2.1.5 [32]. Only freshly isolated primary duck 
hepatocytes can support DHBV (duck hepatitis B virus) infection and consequently 
the initial steps of HBV entry are poorly understood. However, some human 
hepatocyte cell lines are capable of supporting viral replication if transfected with 
viral DNA. 
For HBV and DHBV, several lines of evidence indicate that preS proteins participate 
in cellular receptor binding. First, monoclonal antibodies raised against the HBV L 
protein or DHBV preS protein can block binding of virions. Second, pseudotyped 
virions experiments showed that the block to efficient cross-species infection is at the 
level of virus entry. PreS determinants play the dominant role in host range 
determination. A large variety of proteins have been identified that bind to HBV 
envelope proteins (mostly to the L protein) or to peptides derived from them. A major 
problem has been that none of these molecules has been convincingly tied to 
infectivity. Most probably, hepadnavirus attachment to the cell involves multiple 
components on both the cell surface and the virus envelope. The possibility that a 
complex of several proteins provides functional HBV receptor, like for the human 
immunodeficiency virus (HIV) CD4 receptor and CXR5 co-receptor should be 
considered. However, this view is challenged by a report showing that a synthetic 
epitope, derived from the L protein and, conjugated to beads retains cell attachment 
and uptake capacity [33]. 
The immediate steps following HBV entry are even more poorly characterized and the 
few available data are controversial. Uncoating of the nucleocapsid is thought to 
occur either at the plasma membrane by proteolytic cleavage or in endocytic vesicles 
at low pH.  Almost nothing is known about the delivery of cores to the nucleus. 
Evidence for an implication of the microtubule but not the actin cytoskeleton, in 
intracellular trafficking has been recently presented [34]. 
Finally once in the nucleus, the partially duplex viral DNA is repaired to form the 
cccDNA. Repair requires removal of the 5' terminal structures (an RNA primer and 
the polymerase protein), completion of the dsDNA form as well as covalent ligation 
of the strands. This process does not require HBV polymerase and is probably carried 
out by the host machinery. Whatever the mechanism for the nuclear transport of 
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virion DNA may be, formation of cccDNA, which accumulates only in the nucleus, 
completes the initiation of infection. The cccDNA then acts as a template for the 
transcription of all viral mRNAs. 
 
Transcription 
Mammalian and avian hepadnavirus use the circular 3-kb, cccDNA nuclear form of 
the genome as template for viral transcription (reviewed in [28; 35] and Figure 4). 
There are two classes of transcripts synthesized from the cccDNA known as the 
genomic and subgenomic classes that have been identified in transfected cells and in 
virus-infected livers. Both classes of transcripts are synthesized by the host RNA 
polymerase II, and are polyadenylated at a common polyadenylation sequence within 
the core gene. The polyadenylation site is a non-canonical one known to work 
inefficiently and therefore suitable for the differential use made by HBV. 
Additionally, a sequence called PET (positive effector of transcription) has been 
suggested to facilitate the first passage through the termination site but not the second. 
The subgenomic transcripts function exclusively as messenger RNAs (mRNAs) for 
translation of the X and the three envelope proteins. The two genomic mRNAs encode 
the preC, C and P ORFs. The C/P genomic mRNA (called pregenomic RNA, pgRNA) 
is bifunctional, serving as a template for reverse transcription of the negative viral 
DNA strand in addition to its role in translation of C and P proteins. The longer preC 
mRNA is not used for reverse transcription and functions only in translation of preC 
protein. 
Two enhancer elements (Enh I and Enh II) and four independent promoters (preS1, 
preS2, C and X) control the four ORFs transcription. There is an additional putative 
promoter leading to transcription from the preC gene, which shares with the C/P RNA 
a physically overlapping, but functionally distinct promoter as verified in transfected 
cultured cells. The fine structure and function of individual HBV promoters have been 
well characterized using mainly reporter gene assays, although the transcriptional 
activity of DNA regions has also been investigated in the context of the entire virus 
genome.  
Transcription from the preC/C promoter is highly restricted to liver due to combined 
action of multiple liver-enriched transcription factors regulating transcription both in a 
positive and negative manner. Thus, part of the hepatotropism of HBV is likely 
attributable to liver-specific transcription of the C promoter, which is required for 
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synthesis of the pregenomic RNA. The polymerase-coding region does not have a 
promoter element directly upstream. Its expression is believed to be the result of 
ribosome scanning of the pgRNA transcript. The preS1 promoter directs the 
transcription of the large envelope and its liver-specificity results from its dependence 
on liver-enriched transcription factor like HNF-1. The preS1 promoter functions 
weakly within the context of the virus genome, consistent with low level of L protein 
observed during infection. The S promoter, directing transcription of the gene 
encoding for the (preS2) M middle and S small surface proteins, is constitutively 
active in a wide range of cell types. This promoter lacks a classical TATA sequence, 
accounting for transcription of several mRNAs that do or do not contain the preS2 
translation AUG initiation codon. The mammalian virus X gene mRNA is generally 
of low abundance in vivo, consistent with the low levels of X protein observed. Due 
to proximity with the enhancer region I, the precise border remains controversial. X-
promoter activity involves binding of both liver-enriched and ubiquitous factors. 
Two genomic regions identified as Enh I and Enh II fulfill the classic definition of 
transcriptional enhancer elements (position- and orientation-independent stimulation 
of transcription). Enh I is located upstream of the X promoter and is targeted by 
multiple activators, including basic leucine zipper proteins. Enh II is located upstream 
to the preC promoter and is targeted mainly by nuclear receptors. Enh I functions in 
both hepatic and non-hepatic cells, although it more strongly activates transcription in 
hepatocytes. Furthermore, Enh I strongly upregulates all four major promoters 
whereas Enh II promotes liver-specific transcription of the pregenomic C promoter, 
and possibly the preS2/S promoter. Deletion of either enhancer region results in a 
strong reduction of viral transcripts. Recent studies showed that a functional Enh I is 
required for activation of Enh II, and may thereby regulate global and temporal HBV 
gene expression [36]. 
In eukaryotes, RNA splicing is tightly coupled to export of the RNA from the nucleus. 
HBV transcripts are intronless but nevertheless efficiently accumulate in the 
cytoplasm. The export restriction is overcome by a large RNA element called the 
posttranscriptional regulatory element (PRE) that is also found in the HIV virus (Rev 
response element RRE). The HBV PRE is not dependent on viral proteins for export 
activity. A similar element of the woodchuck virus (WPRE) is used in recombinant 
lentiviral vectors as signal to allow export of the transcripts (D.Trono, University of 
Geneva) 
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 Genome replication 
Translation of the polymerase and pgRNA packaging into viral nucleocapsids are 
tightly coupled events (reviewed in [37; 38]). It is well established that the 
polymerase binds to an RNA stem-loop structure at the 5' end of pgRNA, termed ε 
(epsilon), and that this event triggers the sequestration of viral RNA and polymerase 
(P) into the core particles. The transcription of the pgRNA results in the generation of 
a terminally redundant RNA strand (Figure 6). The redundancy sequence comprised 
of about 200 nucleotides, including the ε stem-loop and a short sequence of 11-12 
nucleotides termed direct repeat 1 (DR1). Another copy of the same sequence is 
located near the 3' end of the RNA and denoted as DR2. Although all HBV transcripts 
harbor a ε stem-loop sequence at their 3' end, only the genomic RNAs harbor them in 
the 5’ position. The 5' stem-loop of the pgRNA is the only one that allows specific 
encapsidation of the pgRNA. In the other preC/C transcripts, initiation from the preC 
AUG (absent in the pgRNA) suppresses recognition of the ε signal. The assembly of 
the polymerase with the ε signal also depends on host factors, in particular the 
molecular chaperone hsp90. The next step in RNA encapsidation is the association of 
the P-ε complex with assembling core subunits. A model, in which the N-terminal 
two-thirds of P protein binds pgRNA, leaving the C-terminus free to interact with 
assembling C polypeptides has been proposed. In hepadnavirus, only polymerase 
bound to stem-loop structures are encapsidated by core proteins. P protein is perhaps 
maintained by the chaperones in a conformation that is competent for interactions 
with assembling C subunits. 
On the contrary, recombinant capsid formation can be obtained independently of 
pgRNA packaging. Deletion of the C-terminal domain of the core protein still allows 
capsid formation but not RNA encapsidation. The fine structure of HBV core particles 
studied by C protein expression in E.coli reveals the presence of two different particle 
structures containing 180 or 240 C subunits. Which particle type can support 
formation of an infectious virion is still unknown.   
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Figure 6: The HBV reverse transcription pathway 
Pregenomic RNA (green) is capped and polyadenylated. The locations of direct repeats 1 and 2 (DR1, 
DR2) are shown in red and the epsilon stem loops are indicated (1). Pregenomic RNA packaging into 
cores is initiated by the interaction of P protein with the 5' copy of epsilon. P initiates reverse 
transcription and extends negative-stranded DNA (light blue) for 3 to 4 nucleotides. P and the 
covalently attached nascent DNA are then transferred to the 3' copy of DR1 (2) and the DNA extended 
(3). During negative-stranded elongation, pgRNA is degraded by the RNaseH activity of P (4), except 
for a small RNA oligomer at the 5' end. This RNA oligomer is, for the most part (90-95%) translocated 
to DR2 (5), where it primes positive-strand DNA synthesis (dark blue) (6).  A second homology-
mediated transfer circularizes the genome (7) and the positive strand is extended for a variable length.  
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The complex mechanism employed by HBV to convert its pgRNA into a double-
stranded DNA inside the nucleocapsid is well characterized and is described in Figure 
6. In addition to its role in RNA packaging, ε plays a major role in the initiation of 
viral DNA synthesis. Upon binding to this three-dimensional structure, the enzyme 
begins to reverse transcribe the pgRNA template for 4 bases. The template for this 
reaction is located in the bulge of the ε RNA. This reaction is unique to 
hepadnaviruses since the polymerase itself serves as a protein primer for DNA 
synthesis. As a result, the polymerase is covalently attached onto the growing 
negative DNA strand. The priming reaction triggers the transfer of the nascent DNA 
strand to the 3' end of the pgRNA, where the 4 nucleotides base pair with 
complementary sequences in DR1. How this transfer occurs is not known but reverse 
transcription can continue from this new site and generates the negative DNA strand, 
which becomes terminally redundant. During negative strand synthesis, the newly 
copied pgRNA template is degraded by RNase H activity of the viral polymerase 
protein. However, 15-18 capped oligoribonucleotides at the 5' end are left undigested. 
This RNA primer is moved and base-paired to the 5' DR2 region on the negative 
strand where it serves as the primer for the positive DNA strand synthesis. Failure of 
this translocation event, occurring at a low rate with wild-type virus genomes (5-
10%), results in the generation of linear double-stranded DNA whose significance in 
natural infection remains unknown. To complete positive strand DNA synthesis an 
intramolecular transfer is required to give the nascent strand access to the uncopied 
portion of the negative strand. Typically, the plus-strand is not completed until re-
entry of the virion into host cells. The final result of the reverse transcription reaction 
is a relaxed circular DNA genome with two modified 5' ends and with a less-than-
genome-length plus-strand DNA. Two explanations for the prevention of total 
genome replication are cited: stearic hindrance or lack of deoxyribonucleic acids 
within the core. In any case, incomplete genomes can be readily found in the secreted 
virions. 
 
Amplification of cccDNA and virion assembly 
Amplification of cccDNA levels takes place in the first few days following infection.  
Its regulation is the basis for establishment and persistence of hepadnaviruses in 
infected hepatocytes and can be expected to play a major role in recovery from an 
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infection. By using DHBV variants, investigators showed that the level of large 
envelope proteins regulated cccDNA accumulation and that this regulation was 
necessary to avoid cytotoxictity induced by high levels of cccDNA in the cells. Once 
higher levels of L protein are reached, subviral core particles segregate into the 
secretory pathway through their interaction with unique determinants on the N-
terminus of the L protein, residing in membranes of the endoplasmic reticulum. The 
myristylation of the N-terminal end of the L protein is not required for virus assembly 
but rather for steps like adsorption, entry and decapsidation. Nuclear transit 
(recycling) seems to be the default pathway of the cccDNA until high enough 
envelope protein accumulation has been reached.  
Assembly processes through the Golgi complex and is completed with the secretion of 
mature virions from vesicular structures into the bloodstream. Recent data in duck 
suggest that viruses mainly spread by secreted, extracellular progeny rather than via 
intracellular particles passing trough cell junctions to neighboring cells [39]. 
 
2.1.5 Available models to study HBV biology 
 
The study of HBV has been hampered by the fact that the virus only grows in humans 
and higher primates. HBV is infectious to chimpanzees [40] and one strain is 
indigenous (species-specific) to chimpanzees in West Africa [41]. Studies with these 
animals (first experimental model of HBV infection) and evaluation of antiviral 
therapies are severely restricted because of their limited availability and high costs. In 
vivo susceptibility of the Asian tree shrew Tupaia belangeri for the human hepatitis B 
virus has been reported [42] and could be a useful model for the experimental analysis 
of various molecular and clinical aspects of HBV infection. However, given the 98-
99% sequence homology between human and chimpanzee, the primate is clearly a 
better model than the more distantly related Tupaia shrew. 
Efforts to understand immune responses to hepadnaviruses in their native hosts have 
been limited largely to descriptive studies. The development of tractable experimental 
systems for the study of HBV immunity now allows analysis of the biological roles of 
T-cell responses to HBV. Transgenic mouse models of HBV infection and disease 
have been developed bearing one or more viral antigen or even an intact replication-
competent viral DNA [43]. The latter mice have the full complement of viral 
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replication intermediates in the liver and release infectious virus into the bloodstream. 
However in these mice, the lack of HBV receptors prevents horizontal spread between 
cells and for unknown reasons, they do not support cccDNA formation. Therefore the 
still-unknown early steps of viral infection, such as virus receptor recognition and 
mechanism of entry, cannot be addressed. Furthermore, complete abrogation of virus 
production by antiviral drugs, which requires elimination of cccDNA, cannot be 
studied in these transgenic mice. New emerging animal models will be discussed 
later. 
 
Animal models based on HBV-related hepadnaviruses, such as woodchuck and duck 
hepatitis viruses are often used for assessment of antiviral drugs and have provided 
important information about factors involved in establishment of virus infection, viral 
persistence, and hepatocarcinogenesis. Basically, one-to 2-day-old ducks are 
inoculated intrahepatically and/or intravenously with plasmid containing the wild type 
or various mutant DHBV genomes. Serum from these animals are then used as 
infectious stocks and inoculated to other ducklings, which are then analyzed for 
various viral parameters like infectivity and growth. However, chronic avian 
hepadnavirus does not appear to be associated with the development of liver cancer 
and therefore precluded investigators from studying these aspects in ducks[44].  
 
 
 
 
Figure 7: Animal models for hepadnavirus 
Woodchuck (Marmota monax), Pekin duck (Anas domesticus) and Tree shrew 
(Tupaia belangeri) 
 
The WHV (woodchuck hepatitis virus) model offers the unique possibility to first 
assay the in vitro replication capacity in transfected hepatoma cells, which are 
permissive for WHV replication. Intrahepatic injection of recombinant DNA then 
allows studying the virus infectious potential in vivo. However, woodchucks 
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(Marmota monax) are relatively large animals of outbred origins that can be found in 
wilderness only in a limited area of the United States, and are difficult to handle in 
many laboratories. 
 
Replication of HBV can be successfully achieved in hepatoma cell lines with cloned 
HBV-DNA genomes delivered by transfection or viral transduction. Various 
constructs of different genome length and under the control of endogenous HBV or 
ectopic promoters are widely used.  To allow for the proper replication gymnastics of 
the virus, the provided HBV DNA has to be more than full length or in the cccDNA 
form. Several groups reported the sustained production of a HBV virus in an in vitro 
system of mammalian origin. The first clones derived from the human cell line 
HepG2 are called HepG2T14 [45] and HepG2.2.15[46]. Altogether these cell-based 
systems have significantly contributed to elucidating various aspects of viral 
replication, and are very useful for production and functional analysis of wild type 
and mutant HBV. However the currently available hepatoma cell lines are not 
permissive for infection with any known HBV. Recently, Gripon et al. described a 
cell line, called HepaRG, which exhibits specific hepatocyte-like morphology, 
expresses specific hepatocyte functions, and supports HBV replication [32]. HepaRG 
cells therefore represent a tool for deciphering the mechanism of HBV entry. They 
also maintain efficient proliferation/differentiation interplay accompanied by 
morphological changes leading to hepatocyte-like cells. Moreover, their close 
resemblance to normal human hepatocytes makes them suitable for many applications 
including drug metabolism. 
 
The first in vitro infection of primary cultures of freshly isolated duck hepatocytes 
with DHBV was demonstrated in 1986 [47]. This avian system is still widely used, 
however the rapid loss of the differentiation stage of primary hepatocytes in culture 
seems to be limiting for continuous infection. Thereafter several groups reported that 
primary cultures of human hepatocytes were susceptible to HBV infection. The 
limited availability and the inherent variability of human liver material hamper the use 
of this model. Although techniques for the isolation of hepatocytes from human livers 
are continuing to improve, primary human hepatocytes are difficult to maintain in 
culture and become nonpermissive for HBV very quickly after plating. To circumvent 
the limited growth and sources problems, technical improvements allowing these cells 
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to remain in an environment that support cell-growth and liver-specific differentiation 
have been proposed. First, long-term immortalization of primary human hepatocytes 
keeping their hepatic features has been successfully achieved [48]. Preliminary 
studies suggest that these immortalized human hepatocytes support HBV replication 
whereas susceptibility to infection is currently investigated (S.Jost; D.Trono personal 
communication). Second, cryopreservation of isolated woodchuck hepatocytes has 
been shown to be a suitable method to stocking problems [49]. This would allow to 
perform infection studies at different time points using hepatocytes isolated from a 
single donor. 
Finally, mice containing livers repopulated with human hepatocytes would provide 
excellent in vivo models for studies on human liver diseases and hepatotropic viruses. 
Partial repopulation (up to 15%) of the liver of the uPA/RAG-2 mouse strain with 
human liver isolated hepatocytes has been reported [50]. Moreover inoculation of 
these transplanted mice with HBV leads to the establishment of productive HBV 
infection. This study is the proof that human hepatocytes can integrate in the mouse 
hepatic parenchyma, undergo multiple cell divisions, and remain permissive for HBV 
in a xenogenic liver. The model of liver repopulation also works with cryopreserved 
woodchuck hepatocytes and provides exciting possibilities to develop novel liver 
experimental models. 
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 2.2 Hepatitis B Virus X protein: a multifunctional viral regulator 
2.2.1 Presentation of HBx 
 
The smallest of the four HBV ORFs encodes a regulatory protein of 154 amino acids 
known as hepatitis B viral X protein (HBx). HBx is well conserved among the 
mammalian hepatitis viruses that all cause liver cancer in their hosts, while no 
obvious counterpart of the HBx gene is found in the non-oncogenic avian hepatitis 
viruses [30]. HBx is essential for establishing natural viral infection [51; 52] and its 
contribution to HCC is supported by a number of circumstantial lines of evidence (for 
reviews, see [3; 53]). However, the basis for HBx function in either process remains 
elusive.  
In cell culture, HBx behaves as a multifunctional protein affecting transcription, DNA 
repair, cell cycle control and apoptosis [54; 55]. HBx has reported functions both in 
the cytoplasm and in the nucleus. HBx is thought to mediate these multiple activities 
through interactions with cellular factors. Indeed, an impressive number of potential 
targets have been reported to bind HBx and are listed in a non-exhaustive manner in 
Figure 8. Previous functional mapping of the 154 amino acids HBx protein pointed to 
two distinct regions between amino acids 50 to 84 and 105 to 142 as being crucial for 
its activities and interactions with cellular proteins [56]. However since then, the 
segment in between was shown to be responsible for interaction with DDB1 [57; 58], 
Hsp60 [59] or mitochondria [60]. The N-terminal part of HBx is involved in 
dimerization and oncogenic properties [61; 62], whereas the C-terminus has inhibitory 
effects on cell proliferation [63]. Hence, all parts of the HBx protein are involved in at 
least one activity or interaction of HBx.  
To study HBx activity, most investigators ectopically express HBx by transient 
transfection or transduction in various cell lines and often under the control of strong 
promoters. Stable cell lines have also been generated that express HBx in a 
constitutive [64; 65] or inducible manner. The inducible systems that were used 
include the tetracycline-regulated [66; 67] and the Cre/loxP recombination system 
[68]. However, sustained HBx expression is somehow detrimental to certain cells as 
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reflected by the failure to establish constitutive HBx-expressing clones in HepG2 and 
Chang cells [64]. Several transgenic mice model have been developed where 
expression of HBx is under the control of an ectopic promoter or under its own 
promoter. These mice were mainly, but not exclusively, used to study the mechanism 
of HBV-associated hepatocarcinogenesis. Table 1 summarizes the available data in 
HBx-transgenic mouse models. 
Table 1: Transgenic mice that express HBx or HBx-deficient HBV 
Regulatory 
region 
Genetic 
background 
Pathology  
observed % 
Other Role of 
HBx 
Reference 
α1-anti-trypsin Outbred None  None Lee (1990) 
HBV Outbred HCC (100%)  Oncogene Kim (1991) 
     Koike (1994) 
   *lower mTERT   Kojima (2003) 
HBV C57BL6/6J None  None Reifenberg (1997) 
Rat insulin C57BL6/6J None  None Reifenberg (1997) 
MUP C57BL6/SJL None  None Guidotti (1990) 
α1-anti-trypsin Outbred None HCC with DEN Cofactor Slagle (1996) 
   HCC with HCV  Slagle (HBV03) 
MUP Outbred None HCC with DEN Cofactor Dandri (1996) 
HBV C57BL/6/DBA2 None HCC with myc Cofactor Terradillos (1997) 
Anti-thrombin C57BL/6/DBA2 None HCC with myc Cofactor Terradillos (1997) 
HBV C57BL6/DBA HCC (86%)  Oncogene Yu (1999) 
   *elevated IL-18  Lee (2002) 
   *HBx upregulated 
by adriamycin 
 Yun (2002) 
HBV C57BL6/6J in process   Xiong (2003) 
HBV ? None HCC with myc Cofactor Lakhatia (2003) 
HBV C57BL6/6J None HCC with DEN Cofactor Zhu (2004) 
HBV C57BL6/6J HCC (60%)  Oncogene Wang (2004) 
      
HBV ∆HBx ? N.A Not essential for 
but enhances HBV 
replication 
 Xu (2002) 
HBV ∆HBx C57BL/6/DBA2 N.A Not essential for 
HBV replication 
 Reifenberg (2002) 
 
* Represents further analysis of the above transgenic mice 
 
In all these systems, the major concern is the high level of HBx expression and the 
absence of the other viral components. Therefore, to assess the function of HBx in the 
context of the viral genome, replication-competent hepatoma cell lines, or duck and 
woodchuck animal models are used (see 2.1.5). Basically, wild type and HBx-
defective HBV genomes are monitored for their replication properties and/or the 
HBx-mediated function of interest. Additionally, more distantly related transgenic 
mouse models assessing in a similar manner the contribution of HBx to viral 
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replication have been reported [69; 70]. It should be kept in mind that the effects of X 
might be strongly dependent on the experimental system, which in no case is the 
natural host for HBV infection. 
 
Regulation of the levels of HBx can be achieved at different levels. The X promoter 
regulates transcription of the small 0.7kb mRNA sequence that encodes HBx. 
Ubiquitous and liver-specific transcription factor binding sites are located in the X 
promoter. The regulation of HBx is complex, involving a variety of signaling 
pathways and autoregulation. Enh I regulates all the HBV promoters, is transactivated 
by HBx and is the target of several signaling pathways (insulin, Il-6). Hypoxic 
conditions were reported to increase HBx expression [71]. Adriamycin, a drug 
commonly used in cancer therapy, has been shown to upregulate at the post-
transcriptional level both HBx mRNA and protein levels [72]. The half-life of HBx 
protein is short [73] and is increased by the interaction with DDB1 [74; 75]. On the 
contrary, coexpression of the HBV core protein reduces the level of HBx protein [76] 
and could explain the low levels of X protein observed during natural infection. 
However, the mammalian virus X gene mRNA is generally of low abundance in vivo 
and could represent another issue consistent with the low levels of X protein 
observed. Though many functions have been associated with HBx, their physiological 
significance for the virus remains in question simply due to the low levels of HBx 
when expressed in the context of the viral genome.  
In vivo, several studies detected the presence of the X protein during the infection. 
For example, woodchuck hepatitis viral X protein (WHx) expression was observed in 
hepatic biopsies during the viremic phase of infection. Some woodchucks even 
develop an immune response to WHx following acute infection [77], as confirmed in 
humans by several studies [78-80] showing that some infected patients develop 
antibodies to X during natural infection. In naturally infected woodchuck hepatocytes, 
Jacob et al [77] showed a cytoplasmic localization of X protein, whereas Dandri et al 
[81] reported both a cytoplasmic and a nuclear localization of WHV X protein. HBV 
X protein has been detected mainly in the cytoplasm of infected human livers with the 
use of high affinity antibodies [82-84].  
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In cell culture, HBx localizes in both the cytoplasm and the nucleus [85]. The 
compartmentalization is dependent on overall expression levels. HBx is 
predominantly localized in the nucleus in weakly expressing cells, whereas its 
accumulation in the cytoplasm correlates with elevated cellular levels [86]. The 
capacity of HBx for nuclear localization may be limited. Cytoplasmic HBx has been 
detected either as perinuclear staining [87; 88] , punctate granules (mostly reflecting 
aggregation of overexpressed proteins) or dispersed patterns.  
 
igure 8: Direct targets of hepatitis B virus X protein 
ouped into three categories: nuclear, 
shuttling or cytoplasmic factors. Some of the signaling pathways affected by HBx are shown in italic. 
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Literature updated version of Figure 1 in [55]. 
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 HBx has been reported to interact with a variety of proteins: cytoplasmic, nuclear, and 
.2.2 Transcriptional modulation by HBx 
 comparison of the genetic organization of HBV with that of complex retroviruses 
results imply that stimulation of transcription may not be a critical function of X 
those that traffic between the cytoplasm and the nucleus. The subcellular localization 
of HBx may be influenced by the amounts of its binding partners, which are different 
in different cell settings and conditions. For example, Crm1 a component of the 
nuclear export machinery has been shown to interact with HBx through a functional 
NES (nuclear export signal) in the C-terminal part of HBx and thereby affect the 
localization of HBx [89]. Interaction of HBx with IκBα [90] and Smad4 [91] affects 
subcellular trafficking of both proteins leading to activation of NF-κB and TGF-β 
signaling, respectively. These reports suggest that the interaction between HBx and 
trafficking molecules may modulate their functions by acting on the nuclear delivery 
of the factors and HBx. The differential influence of HBx binding partners on the 
subcellular localization of HBx could in part explain the multifunctional activities of 
the protein (for reviews, see [54; 55]). 
 
2
 
A
lead to the proposal that HBx may possess transcriptional transactivating activity 
similar to Tat of HIV (human immunodeficiency virus) and Tax of HTLV-1 (human 
T-cell lymphotropic virus type 1).  Indeed, HBx displays a weak to moderate ability to 
stimulate transcription of a wide variety of enhancers and promoters. These include 
viral elements like HBV Enh I and cellular promoters including those of TNF-α, 
FasL, and cyclinA genes among others (an extensive list can be found in [92]). The 
regulatory elements activated by the HBx protein usually contain a DNA-binding site 
for NF-κB, AP-1, c-EBP or NF-AT. Two recent reports analyzed by microarray the 
effect of HBx on transcriptional regulation in human liver cells (HCC cell line or 
freshly isolated hepatocyctes) [93; 94]. Consistent with previous data, HBx affects the 
expression of genes involved in cell cycle regulation, apoptosis, oncogenesis and 
many other cellular functions. In the context of the entire viral genome, expression of 
HBx in some transfected hepatoma cells stimulates accumulation of viral mRNAs 3-
to-8-fold, although no effect on transcription was observed in certain cell lines. These 
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during infection although the situation during natural infection has not been studied. 
Most studies agree that HBx does not act by directly binding to DNA. The nuclear 
function of this protein in transcription is probably due to the reported ability to 
interact with several transcription factors and components of the basal transcription 
machinery (like TATA-binding protein or TFIIB).  
 
2.2.3 Other HBx activities 
 
f HBx activates several cellular signal transduction 
athways, which may contribute to explain its multifunctional properties (reviewed in 
mutual downregulation at the transcriptional 
o produce high yields of virus progeny. However, both anti- and pro-apoptotic 
The cytoplasmic fraction o
p
[95; 96]). Deregulation of normal signal transduction and cellular responses by HBx 
may play a major role in initiation of hepatocarcinogenesis. The modification of 
signaling pathways could also indirectly regulate the activity of transcriptional 
activators. HBx has been shown to activate the Ras-Raf-MAPK signal cascade, the 
stress-activated protein kinases/Jun N-terminal kinase (SAPK/JNK) pathway, the Src 
kinase pathway, the protein kinase B (PKB/Akt) pathway and the Janus kinase/STAT 
pathway. Upregulation of the protein kinase C (PKC) and NF-κB (by acting on the 
inhibitor of NF-κB) have also been proposed. HBx not only affects cellular signal 
transduction but also acts on other pathways by its interaction with proteins involved 
in events like apoptosis or cell growth. 
For example, several findings provide evidence that HBx and p53 are mutually 
inhibitory through direct binding and 
level. The p53 is crucially involved in many pathways governing cell growth or cell 
death. Modulation of HBx activities may be both p53-dependent and p53-independent 
[55].  
Concerning cell death, most viruses are able to delay or block host cell apoptosis in 
order t
activities have been reported for HBx probably reflecting different cellular 
environment. The association of HBx with mitochondria, reported to induce 
mitochondrial dysfunction, [60; 97; 98], could be involved in the apoptotic effects 
modulated by HBx, as mitochondria play a major role in regulation of programmed 
cell death. Another mechanism whereby HBx could affect apoptosis is by modulation 
of cellular Ca2+ signaling [99]. The level of HBx expression and the concomitant 
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fine-tuning of the Ca2+ content could explain the pleiotropic functions and apparent 
discrepancies in the phenotypic effects of HBx expression.  
 
It is important to note that some established activities of HBx (transactivating and 
ro-apoptotic) are conserved among the X proteins encoded by the other mammalian 
 
rongly associated with the development of 
epatocellular carcinoma (HCC), and several lines of evidence indicate an 
106], similar findings were reported by only two of many other studies 
(Table I, [107; 108]). The current model is that HBx does not function as an 
p
members of the viral family [100] and are observed upon HBx expression in the 
context of the entire HBV genome [101].  
 
2.2.4 Role of HBx in HCC development 
Chronic infection by hepatitis B virus is st
h
involvement of HBx in this process. All mammalian members of the hepadnaviridae 
family cause liver cancer in their hosts and share a gene encoding the X protein, 
whereas no counterpart of this gene is found in the non-oncogenic duck hepatitis B 
virus. However the controversial existence and expression of a hidden ORF encoding 
for a HBx-like protein tries to challenge this view [87]. The mechanism of HBV 
induced liver cancer have been spurred by reports showing that HBV DNA is present 
in high-molecular-weight DNA extracted from HCC or from cell lines derived from 
HCC. Since the pattern of DNA integration is random with regard to the cellular DNA 
flanking the viral sequences, integration causing activation of a proto-oncogene is not 
a general mechanism of HBV-induced oncogenesis [102; 103]. HBx, having proposed 
oncogenic properties, is the most frequently integrated fragment of HBV and 
therefore the status of the HBx region has been examined in primary human HCCs 
[104]. C-terminal deletions in the HBx gene are more frequent in tumor-derived 
sequences than in non-tumor derived sequence [105]. The HBx mutants derived from 
HCCs have lost the ability to inhibit clonal outgrowth of cells and to induce apoptosis 
as reported for the wild-type HBx [63]. These findings suggest that truncated HBx 
protein caused by the HBV integration may play an important role in the HCC 
development. 
Since a first study that demonstrated an oncogenic activity for HBx in a transgenic 
mouse model [
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oncogene, but rather acts as a cofactor that contributes to HCC development. 
Expression of HBx together with; exposure to carcinogenic reagents like 
diethylnitrosamine, infection with Hepatitis C Virus or c-myc expression, results in 
increased liver cancer in transgenic mice. Similar findings have been reported in cell 
culture where HBx expression enhances carcinogen-induced mutagenesis and 
cytotoxicity. The multiple activities of HBx may result in the alteration of the balance 
between DNA repair and apoptosis, leading to less efficient repair, a gradual 
accumulation of mutations and an increased probability of neoplasia. A study by 
Livezey shows that HBx induces chromosomal aberration such as chromosome 
rearrangement and micronuclei formation [109]. HBx expression in some cell lines 
increases the proportion of multinucleated cells with multiple centrosomes [97; 110], 
which can be generated by aberrant progression through mitosis. Cells with multiple 
centrosomes will in turn increase the probability of aneuploidy. Centrosomal 
abnormalities and aneuploidy are frequent in many cancers including HCC [111; 112] 
and both have been proposed to play a role in cancer generation (reviewed in [113]). 
Recently, we (Figure S11) and others [114; 115] showed that HBx expression affects 
normal cell growth by inducing mitotic defects even when expressed from the viral 
genome.  
 
2.2.5 Role of HBx in HBV replication 
The molecular function of X protein in the various steps of the viral life cycle has 
 animal models. Wild type HBV genomes or 
Bx-defective HBV genomes are monitored for their amounts of viral RNAs and 
 
been investigated in cultured cells and in
H
DNA replication intermediates. The HBx-dependent stimulation of HBV replication is 
restricted to some hepatoma cells like HepG2 [116] and other people with slightly 
different systems could not detect any defect in the replication of the HBx-defective 
genome [117; 118]. In the HepG2 cell line, a weak increase of viral mRNAs levels 
has been reported upon expression of HBx in HBV-genome transfected cells. The 
activation of Src kinases but not Ras by X protein was found to stimulate HBV and 
WHV replication in hepatoma cell lines [119]. In this system, ablation of HBx 
expression by mutation of the X gene impairs HBV DNA replication 5- to 20-fold. 
The effects are thought to be mainly but not exclusively at the post-transcriptional 
 48
level. Robert Schneider's group further showed an HBx-mediated calcium stimulation 
of HBV replication by acting on stored cytosolic calcium [120; 121]. However this 
calcium dependent stimulation of replication could not be reproduced by others, who 
instead show that HBx affects replication through a proteasome-dependent pathway 
[122].  
X protein has been shown to be essential for viral proliferation in the woodchuck. 
Ablation of the X gene blocked establishment of infection [51; 52]. A recent study 
argues that X-deficient WHV mutants behave like attenuated viruses with a low level 
of replication [123]. By contrast for the duck model, a recent study showing no role 
for the controversial DHBx protein in in vivo infection is available [124]. Transgenic 
mice models [69; 70] showed that while the HBx gene product is not essential for 
HBV replication or its maturation, it can enhance viral replication. The well-accepted 
essential function of the X protein in hepadnaviral replication still remains unknown. 
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 2.3 Damaged DNA-binding protein 1  
2.3.1 Presentation of DDB1  
 
Using yeast two-hybrid assays, several groups including our team isolated DDB1 as a 
binding partner of HBx [57;58 ;125]. DDB1 is a protein originally described to form 
with DDB2 the UV-DDB complex that binds to UV-damaged DNA. DDB1 orthologs 
exist in many organisms including yeast, worms, flies, chicken and even in plants. 
Figure 9 shows that DDB1 is highly conserved. For example, the S.pombe and human 
DDB1 proteins share 46% sequence homology, with three domains of 66, 58 and 35% 
homology that are conserved among other species [126].  
 
Figure 9: DDB1 is a highly conserved protein 
Alignment of Arabidopsis DDB1A (NP_192451) with Arabidopsis DDB1B (NP_193842), as well as 
homologs from rice (Os BAB20761), human (Hs = DDB1_HUMAN), Drosophila (Dm = XP_081166), 
and S. pombe (Sp = NP_593580). Identical residues are shaded. Horizontal bars overlay peptides 
identified at 50 ppm accuracy in tobacco DET1-interacting protein. [127] 
 
In contrast to DDB1, the DDB2 subunit is less well conserved, and there are no clear 
orthologs in the sequenced genomes of Drosophila, C.elegans, or S.pombe. The high 
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evolutionary conservation of DDB1, but not of DDB2, suggests that DDB1 carries out 
important functions in the cell independently of DDB2 [126; 128]. It is possible that 
the basal function of DDB1 has been adapted to a DNA repair / transcription function 
through association with DDB2 in higher eukaryotes.  
The human DDB1 is a large protein of 1,140 amino acids consisting mainly of 
WD40-related repeats predicted in silico by Markov's model analysis to fold into B-
propeller blades [129]. The position and number of these repeats are remarkably 
conserved in S.pombe Ddb1 (15 repeats in yeast versus 17 in humans), suggesting that 
the overall structure and function of the two proteins might be similar. Attempts to 
define the structure of human DDB1 are under way in N.Zheng's lab (University of 
Washington, Seattle), and preliminary data suggest a highly structured protein 
(N.Zheng, personal communication). 
  
The expression profile and functions of the DDB1 orthologs in various organisms are 
currently being unraveled. Unfortunately available data are only sparse and do not 
allow at the moment to pinpoint to a conserved function of DDB1. Nevertheless some 
observations concerning DDB1 orthologs are listed below. For example, Arabidopsis 
DDB1 interacts with the nuclear protein DET1 involved in regulation of 
morphogenesis and gene expression in response to light [127]. The rice homologs of 
UV-DDB proteins are most abundant in proliferating tissues [130] and rat UV-DDB 
homologs possess tissue-dependant expression [131]. Analysis of drosophila DDB1 
reveals that its expression levels are high when DNA replication is maximal 
suggesting that DDB1 acts as a cell proliferation- or development-associated factor as 
well as a repair factor [132]. Consistent with observation in human cells, DDB1 
localization is both nuclear and cytoplasmic but UV-irradiation or DDB2 
coexpression leads to strictly nuclear relocalization of DDB1 in drosophila [132] or 
chicken orthologs [133] of DDB1, respectively.  
Analysis of the human DDB1 and DDB2 promoter regions suggests a regulation of 
basal transcription typical of cell cycle regulated genes [134]. In drosophila 
transcription of the DDB1 gene is under control of the DRE/DREF system, known to 
regulate the expression of several genes encoding cell cycle regulated factors [132]. 
However, a transcriptome analysis in HeLa cells did not identify DDB1 and DDB2 as 
being cell cycle regulated [135]. The level of DDB1 and DDB2 protein peaks at the 
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G1/S boundary and decreases abruptly in S phase in regenerating mouse livers [136; 
137]. This regulation may involve cullin-4A [136], a member of the cullin family of 
proteins that act as scaffolds for the assembly of E3 ubiquitin ligases which transfer 
ubiquitin to target proteins, either modifying their activity, or more usually, targeting 
them for degradation [138]. Cullin-4A associates with the DDB1 subunit and when 
overexpressed stimulates degradation of DDB2 through the ubiquitin-proteasome 
pathway [136;139;140]. The finding that increased cullin-4A expression, which is 
found in some breast cancers, leads to increased turnover of DDB2, led to the 
suggestion that this may contribute to tumor development [136].  Recently, DDB1 has 
been reported to be integrated into two complexes of identical protein composition, 
except for the exclusive presence of DDB2 or CSA (Cockayne syndrome protein A). 
Both complexes contain cullin-4A, Roc1 and the COP9 signalosome; display 
ubiquitin E3 ligase activity; and they both are involved in nucleotide excision repair 
[141]. Other multiprotein complexes involved in protein degradation containing 
DDB1 and cullin-4A have been reported for: SV5-V (Simian virus 5 protein V, see 
below) and human DET1 promoting the degradation of STAT1 and c-Jun, 
respectively [142; 143].  
The cytosolic fraction of human DDB1 has been reported to bind to the Alzheimer 
amyloid precursor protein [144], however whether and how DDB1 might be involved 
in neurodegenerative processes remains unknown. 
 
2.3.2 The UV-DDB complex 
 
DDB1 is the large subunit of a complex called UV-DDB that was first isolated as a 
factor that binds to UV-damaged DNA and that is defective in a subset of patients 
suffering from the Xeroderma pigmentosum (XP) disease. This disease is a 
multigenic, multiallelic autosomal recessive disease that results in an inability to 
repair DNA damage from ultraviolet (UV) light. Heterozygotes are unaffected, but 
homozygotes have severe sun sensitivity that leads to progressive degeneration of 
sun-exposed regions of the skin and eyes, usually leading to various forms of 
cutaneous malignancy (melanoma and nonmelanoma) [145]. Progressive neurologic 
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degeneration occurs in a significant number of patients, which can be correlated with 
mutations in specific XP genes. 
Cells from a subset of XP patients in complementation group E (XP-E) were 
demonstrated to lack an activity that recognizes UV-damaged DNA with high affinity 
[146]. Subsequent purification showed that this activity comprised two proteins of 
127 kDa and 48 kDa, now called DDB1 and DDB2, which together form the UV-
DDB complex [147]. Injection of UV-DDB restored nucleotide excision repair 
activity to cells from XP-E patients [148; 149]. UV-DDB has more recently been 
implicated in global genomic nucleotide excision repair [150; 151], and it rapidly 
accumulates at DNA damage sites upon exposure of cells to UV irradiation [152]. The 
association of STAGA (a chromatin-acetylating transcription coactivator) with DDB1 
[153] could perhaps facilitate the assembly and/or function of the NER machinery on 
nucleosomes. 
The DDB2 subunit is the regulatory factor of the UV-DDB complex. DDB2 protein 
levels increase in response to UV irradiation through transcriptional stimulation of the 
DDB2 gene by a p53-dependent mechanism [150], which then allows DDB2 to 
mediate nuclear import of the otherwise cytoplasmic DDB1 protein [154]. Although 
the damaged-DNA binding function of UV-DDB requires both subunits [155; 156], to 
date mutations in XP-E patients have only been found in the DDB2 subunit 
[146;157;158]. Interestingly, UV-DDB activity is largely deficient in rodent cells due 
to low expression of DDB2 [159]. DDB2 gene disruption in mice leads to skin tumors 
and resistance to apoptosis after exposure to ultraviolet light [160]. These results 
demonstrate that DDB2 functions as a tumor suppressor, by controlling p53-mediated 
apoptosis after UV-irradiation. On the other hand, overexpression of DDB2 in 
primary fibroblasts appears to be toxic, presumably due to the disturbance of normal 
p53 regulation [161]. The c-abl tyrosine kinase activated by some forms of DNA 
damage binds to the UV-DDB complex through the DDB1 subunit and is thereby 
suggested to negatively regulate UV-DDB activity by phosphorylation of DDB2. 
These post-translational protein modifications represent a new form of DDB2 
regulation [162]. Concerning HBV biology it is important to note that c-Abl also 
binds RFX1, a protein known to bind to and activate the Enh I of HBV [163; 164].  
A role for UV-DDB other than in DNA repair has also been suggested. UV-DDB 
functionally interacts with the cell cycle transcription factor E2F1 to stimulate 
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transcription of E2F1-regulated genes, suggesting that it plays a role in the cell cycle 
[140; 163]. It has also been reported that UV-DDB recruits the p300/CBP histone 
acetyltransferase complex to chromatin [163; 165]. Recently, DDB1 and DDB2 have 
been shown to be part of a complex bound to the PKR promoter [163; 166]. Though it 
is presently unclear whether these observations are related to a role in regulating gene 
expression, or DNA repair. 
 
2.3.3 Role of DDB1 in cell cycle regulation 
 
The investigation of the role of DDB1 in S.pombe is important because its function is 
assessed in the absence of DDB2. Recent analyses of mutant S.pombe strains lacking 
expression of the Ddb1 gene reveals that the gene is not essential but its product is 
somehow involved in cell cycle regulation. The S.pombe Ddb1 protein has been 
shown to be required for normal cell growth, progression through the S phase and 
proper chromosome segregation [167-169], (A.Krapp and V.Simanis, personal 
communication). Further evidence suggests that Ddb1 is functionally linked to the 
replication checkpoint control gene cds1 by increasing its activity. The regulation of 
Cds1 is performed by another protein called Spd1 whose proteolysis is cooperatively 
regulated by the Cop9/signalosome and Pcu4. Interestingly, Spd1 proteolysis is 
implicated in the regulation of the ribonucleotide reductase supplying 
deoxyribonucleotides for DNA replication and repair [187].  Bondar et al. show [167] 
that DDB1 also plays an essential role in the proteolysis of Spd1. Preliminary studies 
of DDB1 knockdown in C.elegans (P.Gönczy, personal communication) and in HeLa 
cells (Figure S8) are consistent with a defect in DNA replication. The repeated reports 
of the presence of DDB1 in degradation complexes with E3 ubiquitin ligase activity 
implicated in various cellular functions argues in favor of a large palette of 
phenotypic features upon DDB1 deletion. 
 
2.3.4 DDB1 as a target for viral proteins 
 
Intriguingly, DDB1 is also a potential target for another viral accessory protein that 
shows no similarity to HBx. DDB1 interacts with the V protein encoded by several 
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members of the Paramyxoviridae family including simian virus 5 (SV5). The role of 
the V proteins in the viral life cycle remains to be fully established, but evidence 
exists that the protein is essential for pathogenicity of these viruses in the natural host. 
These viruses are well known human (measles virus, mumps virus) and animal 
pathogens and newly emerging agents (such as Hendra and Nipah viruses) have been 
recently identified. Simian virus 5 is a member of the Rubulavirus genus. These 
viruses share the following features: 1) the genome is characterized by a non-
segmented negative sense RNA of 15-20 kb; 2) the genomic RNA is tightly bound to 
the nucleocapsid to form an helical structure; 3) the initiation of primary transcription 
by a virion-associated RNA dependant RNA polymerase; and 4) a cytoplasmic 
replicative cycle. The SV5 genome contains seven genes that encode 8 proteins: the V 
and P protein are both transcribed from the V/P gene by a process termed 
pseudotemplated transcription. The SV5-V mRNA is a faithful copy of the V/P gene, 
whereas the P mRNA contains 2 nontemplated G residues, which are added by viral 
polymerase stuttering. As a result, the SV5-V and P proteins share 164 amino-
terminal amino acids but have distinct carboxyl-terminal domains. The unique C-
terminal domain of the V protein is highly conserved among the paramyxoviruses. 
The interaction of SV5-V and DDB1 involves the conserved carboxyl-terminal 
domain of the viral protein. Consistent with this notion, V proteins of the mumps 
virus, human parainfluenza virus 2 (hPIV2) and measles virus have also been found to 
interact with DDB1. The V protein of SV5 and of other paramyxoviruses exhibits the 
well-characterized ability to block interferon signaling, and thereby the induction of 
an antiviral state, by specifically targeting STAT proteins for proteasome-mediated 
degradation. Both, the C-terminal conserved domain [170] and the common N-
terminus [171] are involved in SV5-V mediated STAT1 degradation [172].  
The binding of SV5-V to DDB1 has been documented to slow the progression of the 
cell cycle [173], yet another study with lower expression of SV5-V challenges this 
report [174]. Recently a role for DDB1 in STAT1 protein degradation induced by the 
SV5-V protein has been demonstrated in our lab (Publication 2 Figure 5) and in 
Randall's lab [175]. DDB1 is essential for SV5-V-induced STAT1 degradation 
probably by acting as a bridge between the cullin-4A and the viral substrate adapter 
factor SV5-V. Indeed, the assembly of V-dependent degradation complex that 
includes STAT1, STAT2, DDB1 and Cul4A has been demonstrated [142]. 
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2.4 Aim: study of the HBx-DDB1 interaction 
 
This section describes the aim of my thesis. First, the data about the HBx-DDB1 
interaction known at the start of the thesis will be summarized and will allow to 
define the overall directions of the project. The data obtained are presented in the 
Results section (chapter 4).  
HBx has been known for some time to interact with DDB1 [58; 125], but the 
significance of this interaction has remained quite elusive. Nathalie Lin-Marq, a 
former member of the laboratory, isolated DDB1 as the only HBx-interacting protein 
in an extensive yeast two-hybrid screening assay. It is important to emphasize that 
among the many protein reported to interact with HBx, DDB1 is the only one that was 
isolated by three different labs. Further mutational analysis of HBx allowed to define 
the region (amino acids 76-125) and residues involved in DDB1 binding. Our data are 
consistent with reports showing that the minimal region of HBx required for 
interaction with DDB1 resides in the central part of the viral protein: amino acids 55-
101 [176] and amino acids 66-101 [58]. It is worth mentioning that binding to DDB1 
is a feature conserved among mammalian hepadnavirus X proteins [58].  
The first HBx function investigated in the laboratory was its ability to transform 
primary cells. No evidence was obtained that expression of HBx induces 
transformation in cooperation with known oncogenes such as E1A or c-myc.  In the 
course of these studies, the laboratory rather found that HBx actually prevents 
oncogenes from transforming cells. Further analysis revealed that HBx expression 
induces a loss of cell viability of both primary and immortalized cells. A mutational 
analysis of HBx in which charged amino acids were specifically targeted with the aim 
of identifying interacting residues revealed a strict correlation between DDB1-binding 
and cytotoxic activities. This knowledge about the HBx-DDB1 interaction represented 
the starting point of the thesis.  
 
The first part of my thesis is aimed at providing compelling evidence that binding of 
HBx to DDB1 is indeed essential for its anti-proliferative activity. One mechanism 
whereby HBx may exert its effect is by sequestering DDB1, thereby preventing it 
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from performing a function that might be essential for cell survival. To test this 
hypothesis, we will observe the effect of DDB1 overexpression on HBx activity. 
Another mechanism that could mediate HBx activity is to force DDB1 into a yet to be 
discovered function or by conferring new activities to the protein. For this, we will 
artificially tether an inactive HBx(R96E) mutant to DDB1 and assess its cytotoxic 
activities. These experiments will hopefully allow to provide direct evidence that an 
interaction of HBx with DDB1 is critical for its activity.  
The characterization of the molecular mechanisms whereby HBx mediates its 
antiproliferative activity upon binding to DDB1 represents the second and main part 
of my thesis. The first question to ask was in which subcellular compartment does 
HBx, function in conjunction with DDB1. Séverine Bontron could show that the 
nuclear fraction of HBx is responsible for mediating cell death and that HBx enters 
the nucleus independently of both UV-DDB subunits. Determination of the regions 
and activities of DDB1 that are important for the HBx-mediated growth suppressive 
effect was the next step. To address this question, we will initiate a structure/function 
analysis of DDB1 that should allow to map the HBx-binding domain of DDB1 and 
other regions in the protein that are functionally important with respect to HBx 
cytotoxicity or other DDB1 functions. A detailed comparison of SV5-V (another viral 
partner of DDB1) and HBx proteins in regard of DDB1 binding properties will allow 
us to unravel some aspects of the mechanism governing HBx-mediated interference 
with cell viability. For example, we will ask whether HBx, DDB2 (the natural partner 
of DDB1) or SV5-V can bind DDB1 simultaneously or in a mutually exclusive 
manner. This will be addressed by using competitive co-immunoprecipitation and 
yeast protein-protein interaction assays in presence of an excess of one or another 
DDB1-binding partner. Additional investigation of the role of SV5-V binding to 
DDB1 will be performed and perhaps allow us to pinpoint to DDB1 activities other 
than the one reported in conjunction with DDB2. Furthermore, cellular components 
interacting with DDB1 alone or with the DDB1-HBx complex will possibly be 
identified in a yeast two-plus-one hybrid screen using DDB1 as bait in the presence or 
absence of HBx. 
Another important issue will be to decipher in molecular terms the nature and order of 
events along the pathway that links HBx-DDB1 complex formation to cell death. The 
suppression of colony formation is a very indirect measure to determine the effect of 
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HBx on cell growth.  Therefore we will investigate more precisely the phenotype 
induced by HBx and assess the depicted cell cycle defects. 
 
Finally, the functional relevance of the HBx-DDB1 interaction during viral infection 
will be assessed. In woodchuck, the X protein is essential for WHV replication [51; 
52] and in human hepatoma cells, the HBV replication is significantly dependent on 
expression of HBx [116]. Whether and if so, how the HBx protein requires interaction 
with DDB1 to stimulate HBV replication is unknown. To address this question, we 
will take advantage of our knowledge of the mechanism of HBx-DDB1 interaction 
and try to complement the replication deficiency of a HBx-deficient HBV genome by 
various HBx variants. If this interaction is required for efficient viral replication in 
hepatoma cells, studies in woodchucks could be envisaged as an animal model to test 
antiviral drugs that block the DDB1-HBx interaction. 
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3.Materials and Methods 
 
This section complements Materials and Methods from the different publications. 
 
3.1 Expression constructs 
 
All recombinant DNA work was done according to standard procedures.  
The deletion mutants of HBx were obtained by PCR amplification and cloned into 
expression vector EBO-76PL. All clones were confirmed by sequencing of the open 
reading frame. Fusion of the HBx mutant HBx(L98F) and HBx(∆C14) was performed 
as for the HBx(R96E) [57]. 
The NES-DDB1 was constructed by fusing the NES motif to DDB1 as reported for 
HBx in [85].  
Plasmids pcDNA-MYC-CUL-4A (myc-tagged mouse CUL-4A) and pcDNA-F-CUL-
4A (Flag-tagged human CUL-4A) were generous gifts from P.Zhou (Department of 
Pathology, Cornell University, New York) [139]. The CUL-4A specific small 
interfering RNA (siRNA)-like transcript was expressed as reported for the DDB1-
specific construct [75]. The CUL-4A targeting sequence was directed against 
nucleotides 1670 to 1688 of the CUL-4A coding region (top strand 5'- 
GATCCCCTGGAGAGTTCAAGCACAAGTTCAAGAGACTTGTGCTTGAAC
TCTCCATTTTTGGAAA-3').   
The DDB1 variant non-siRNA susceptible was obtained by introducing three 
mutation at the third codon position at nucleotide 3253, 3256 and 3259 within the 
siRNA targeting sequence of the DDB1 coding region.  The mutated nsi-DDB1 clone 
was confirmed by sequencing before transfer into yeast and mammalian vectors. 
For IFN signalling studies, plasmids and experimental procedures are presented in 
[177]. 
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 3.2 Cell cycle analysis by flow cytometry 
 
Cells were trypsinized, pelleted, and fixed O/N with 70% cold ethanol. Samples were 
resuspended in a solution containing propidium iodide and subjected to FACScan 
analysis. 
3.3 Fluorescence microscopy 
 
Cells were grown on coverslips and transfected. 1-2 days after transfection, cells were 
fixed in 3.7% formaldehyde in phosphate-buffered saline and stained with 5 µg/ml 
Hoechst 33342 (Sigma), stained with various antibodies (anti-α-tubulin, Sigma; anti-
TPX2, kindly provided by H.Heidebrecht at the University of Kiel) and coverslips 
were mounted onto glass slides using Mowiol 4-88 (Calbiochem). Cells were viewed 
and acquired in a Zeiss Axiophot fluorescence microscope (Figure S5 and S8) or in a 
Zeiss confocal microscope LSM 510 (Figure S3).  
3.4 Yeast two-plus-one-hybrid assay 
 
DDB1 was joined to the carboxyl-terminus of RFX to produce RFX.DDB1. This 
construct was inserted into a URA3 centromeric plasmid between the regulatory 
sequences derived from the yeast TBP gene.  The constructs expressing native SV5-V 
or HBx proteins and the VP16 activation domain-tagged cDNA library were 
described previously [57; 75]. 
The two-plus-one-hybrid screen and the β-galactosidase assay were performed 
essentially as described [57; 75]. 
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4.Results 
 
Most of the results obtained during this thesis have been the subject of two 
publications and one manuscript in preparation, which are presented in the following 
section. Additional unpublished results are also presented. 
During the course of this thesis, the nomenclature in regard of the UV-DDB subunits 
has slightly changed. The large subunit is called p127 in the first publication and then 
DDB1, whereas the small subunit previously named p48 is now DDB2. 
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4.1 Hepatitis B virus X protein interferes with cell viability through 
interaction with damaged DNA-binding protein-1 (DDB1). 
 
 
 
4.1.1 Publication 1: Virology 287, 266-274 (2001) 
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4.1.2 Additional structural data about HBx 
 
Using the yeast two-hybrid system, we tested different amino- and carboxyl-terminal 
deletions of HBx for their ability to interact with DDB1 (Publication 1 Figure 3). 
These studies delimited the DDB1-interaction domain within amino acids 76 and 125. 
Additionally, of the 12 tested charge reversal mutations in HBx, two are lacking 
cytotoxic activity and both lack DDB1 binding. We therefore assessed whether 
binding to DDB1 is the only activity needed for HBx-mediated cytotoxic activity in 
mammalian cells. We therefore tested several amino-terminal deletions of HBx for 
their ability to interfere with cell viability. The N-terminal part of HBx has been 
shown to be required for HBx dimerization and oncogenic properties [61; 62]. Upon 
transfection into HeLa cells only HBx protein variant lacking the first 44 amino acids 
remained cytotoxic; further deletion results in proteins lacking this activity (Figure 
S1A). Hence, amino acids 45 to 75 are also indispensable for HBx-mediated cell 
death. The results therefore suggest that binding to DDB1 is not sufficient to induce 
cytotoxicity. However, one should consider data from deletion mutants with caution. 
Discrepancies with yeast data could be due to steric hindrance of the GFP sequences 
whose C-terminus was connected to the amino-terminal HBx deletions whereas yeast 
RFX fusions were connected the other way round. However, the same results were 
obtained when the HBx amino-terminal deletions were expressed in their native form 
(data not shown), arguing in favour of a role of amino acids 45 to 75 in HBx-mediated 
cytotoxicity although they are not part of the minimal DDB1-binding domain. These 
results could be useful to delimit the smallest functional domain of HBx in order to 
produce large quantities of the protein for X-ray crystallography. 
 
We found that connecting DDB1 to the HBx (R96E) derivative rescues the cytotoxic 
activity of this otherwise inactive mutant, showing a need for DDB1 -HBx interaction 
to induce cell death. We tested the activity of two other HBx derivatives when fused 
to DDB1. The HBx(L98F) mutant behaves as HBx(R96E) for binding to DDB1 in 
yeast and induction of cell death whereas an HBx derivative deleted of the 14 last 
amino acids HBx(∆C14) still interacts with DDB1 in yeast but has an intermediate 
toxic phenotype. Deletion of 14 amino acids at the C-terminus of HBx has been 
shown to abrogate the suppressive effects of HBx on cell growth [63]. When 
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connected to DDB1, the HBx(L98F) mutant regains much of its activity (Figure S1B). 
An intermediate phenotype with respect to toxicity was observed when the 
HBx(∆C14) was fused to DDB1. Although the 14 last amino acids are not conserved 
in the woodchuck hepatitis virus WHx protein, which also exhibits cytotoxicity, these 
terminal amino acids seem to be involved in interference with cell viability. To date 
this mutant is one of only two HBx mutants (the other mutant being the 
K113R/D114R) that show binding to DDB1 in yeast but an impaired cellular 
cytotoxicity. Whether, and if so, how these residues are responsible for this activity 
remains to be elucidated. The same interference with cell viability was reported for 
the only 140 amino acids long woodchuck X protein. Therefore the HBx(∆C14) 
mutant probably depicts a structural problem rather than an absence of interaction 
with a putative partner responsible for induction of cell death. 
 
igure S1: Functional analyses of HBx amino-terminal truncation and point mutants 
erminal amino acids are dispensable for HBx-mediated cytotoxicity. HeLa cells 
ere transfected with EBO-76pl-derived episomal vectors expressing the indicated GFP-HBx variants 
ransfected into 
vect HBx HBx-DDB1
HBx(R96E)
-DDB1
HBx(L98F)
-DDB1
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fused to DDB1  
 
A) The 44 first N-t
w
and bearing a hygromycin resistance gene. Transfection efficiencies were assessed by FACS analysis. 
Drug-resistant cells were fixed and stained with crystal violet 9 days after transfection. 
B) The DDB1-binding defective HBx(L98F) mutant regains activity when fused to DDB1. Plasmids 
expressing the indicated HBx proteins as N-terminal fusion to DDB1 (- DDB1) were t
HeLa cells. A GFP gene was cotransfected to assess for comparable transfection efficiencies by FACS 
analysis. Colony formation assay was performed as in A).  
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 4.1.3 HBx-induced phenotype: disturbing the cell cycle progression 
 
The ability of HBx to interfere with cell viability, a property documented to reflect its 
potential to induce apoptosis, requires association of HBx with DDB1 in the nuclear 
compartment [85]. Previous work (Annexin V staining) and this work (caspase-
mediated proteolytic and DNA cleavage) did not allow to detect any induction of 
apoptotic cell death upon expression of HBx. When ectopically expressed in human 
cells, HBx induces severe morphological changes and cell death. The observed 
morphological abnormalities include the appearance of increasing numbers of nuclear 
aberrations, basically multinucleated cells and micronuclei (Figure S2A). This 
phenotype prompted us to investigate the DNA content of HBx-expressing cells at 
different time points after transfection. Drug-resistant cells were stained by propidium 
iodide and analyzed for their DNA content by flow cytometry. Three days after HBx 
transfection, the staining revealed an increased number of cells with 4N, whereas 
HBx(R96E)-expressing cells showed a typical profile of asynchronous cells with the 
Figure S2: HBx-expressing cells show altered morp
majority of cells in Go/G1 (2N) (data not shown).  
hology and aberrant DNA content  
rug-resistant cells were selected with hygromycin. Nuclei were visualized by staining with the DNA 
 cells were 
stained with propidium iodide and their DNA content assessed by FACS analysis.  
A
Mock
Vect GFP-HBx GFP-HBx(R96E)
B
1 2 3 4
 
A) Altered morphology upon HBx expression (panels 1-4). HeLa cells were transfected with HBx and 
d
marker Hoechst 3342  (Blue, panel 2 and 4). Panel 1 shows a light microscopy picture of HBx-
expressing cells whereas panel 3 and 4 show tubulin immunofluorescence (green) staining. 
B) Expression of HBx leads to cells with more than 4N DNA content. Flow cytometric analysis of 
HeLa cells transfected with GFP-HBx variants. Ten days after transfection, drug-resistant
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A large number of cells with a more than 4N DNA content could be observed in a 
DDB1-dependant manner after 10 days of HBx expression (Figure S2B).  The cells 
er of cells in anaphase and 
es 
ere stained with TPX2 (red) and DNA with TOTO-3 (white). Cells with lagging chromosomes and 
 aberrant centrosome numbers depends on HBx 
teracting with DDB1, since the HBx(R96E) mutant unable to bind DDB1 did not 
how this phenotype. In principle, lagging chromosomes and chromosomal bridges 
with a DNA content superior to 4N could already be detected as soon as day 3 post 
HBx transfection. These multinucleated cells may arise either through aborted cell 
division or as a result of cell fusion. To test the latter hypothesis, cells expressing 
GFP-HBx were mixed with RFP expressing cells. Almost no double-colored cells 
were observed, even when multinucleated (data not shown), arguing in favour of a 
defect in cell cycle regulation rather than a fusion event. 
Microscopy studies showed that as early as 48h after transfection in HeLa cells, HBx 
expression produces a significant increase in the numb
telophase showing lagging chromosomes and/or chromosomal bridges (Figure S3).  
defects.  
(By courtesy of Silvia Martin-Lluesma) Two days after GFP-HBx transfection in HeLa cells, spindl
Lagging 
Chromosomes
Abnormal
spindles
Multinucleated
cells
 
Figure S3: Binding of HBx to DDB1 affects normal cell growth by inducing mitotic 
w
multipolar spindles were scored in GFP-positive cells. These features are also observed in the 
hepatoma cell line HepG2 (data not shown).  
 
 
Abnormal spindles architecture due to
in
s
could be generated either by stalled replication forks or sustained cohesion. Both 
cases would ultimately lead either to proper resolution of the knots, to chromosomal 
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breaks or to complete mitotic failure, producing a mixed cell population including 
normal cells, aneuploid cells, micronuclei and multinucleated cells with multiple 
centrosomes. After a number of cell divisions, this population will show increased 
number of aberrations, and eventually cell death. Available data from the lab (Silvia 
Martin-Lluesma, personal communication) suggest that HBx expression leads to a 
longer S phase probably by acting at the level of replication initiation. 
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igure S4: HBx-mediated toxicity is p53-independent.  
epG2 cells were transduced with a siRNA lentiviral vector direct against p53 (LV-THsi-p53) or a 
 transduced with a second lentiviral 
cells were stained with crystal violet 
hese mitotic defects induced by HBx as well as HBx toxicity were observed in HeLa 
ells that express low levels of wild-type p53 protein, which is presumed to be altered 
H
control vector (LV-TH). 12 days after transduction, the cells were
vector expressing either GFP-HBx or GFP-HBx(R96E). Surviving 
16 days after HBx expression.   
 
 
T
c
in function as a consequence of its association with HPV E6 oncoproteins [178]. The 
p53 protein was shown to be important for the control of different cell cycle 
checkpoints. We therefore asked whether p53 was involved in HBx-mediated 
cytotoxicity. First, presence of multiple spindles and lagging chromosomes could also 
be detected in a p53-positive hepatoblastoma cell line, HepG2 (data not shown). To 
further assess the role of p53 in HBx activity, HepG2 cells were first transduced with 
a lentiviral vector directing synthesis of a siRNA against p53 (kindly provided by 
M.Wiznerowicz) or with empty vector [179]. In a second stage, cells expressing close 
to undetectable levels of p53 (data not shown) were transduced with different HBx-
expressing viral vectors. The HBx-mediated cytotoxic phenotype was shown to be 
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p53-independent since both; p53 positive and p53 knockdown, cells showed reduced 
viability (Figure S4). This effect was again dependent on HBx binding to DDB1 since 
HBx(R96E) did not alter cell growth. Additionally, the Hep3B cells in which a 
functional p53 is absent showed the same HBx-mediated cytotoxicity (data not 
shown) further confirming that this phenotype is p53-independent as reported for 
other HBx-mediated activities.  
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4.2 Hepatitis B virus X protein and simian virus 5 V protein exhibit 
similar UV-DDB1 binding properties to mediate distinct activities. 
 
4.2.1 Publication 2: Journal of Virology 77, 6274-6283 (2003) 
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4.2.2 Additional data about the interaction between SV5-V and DDB1 
 
 
We demonstrated the binding of SV5-V to DDB1 in yeast and mammalian cells [75] 
but we decided to further investigate this interaction in mammalian cells. As a first 
experiment, we tried to show by fluorescence microscopy an interaction between 
DDB1 and SV5-V. An N-terminal GFP variant of SV5-V showed a predominantly 
nuclear distribution as reported previously [174]. DDB1 also being mainly nuclear 
due to its DDB2-mediated nuclear import, we used a DDB1 variant fused to a nuclear 
export signal (NES) to assess whether cytoplasmic DDB1 would relocate SV5-V from 
the nucleus to the cytoplasm. Indeed upon cotransfection with NES-DDB1, GFP-
SV5-V relocates mostly to the cytoplasm (Figure S5).  
GFP Hoechst Merge
GFP-SV5-V 
+ vect
GFP-SV5-V 
+ NES-DDB1
 
Figure S5: SV5-V interacts with DDB1 in mammalian cells 
 
Hela cells cotranfected with the GFP-SV5-V and either empty vector or a DDB1 variant engineered to 
be excluded from the nucleus (NES-DDB1) were fixed at 2-day postransfection, and the GFP protein 
was visualized by fluorescence microscopy (left column). Nuclei were visualized by staining with the 
DNA marker Hoechst 3342 (middle column); overlay is shown in the right column. The effect of 
overexpressing NES-DDB1 on the intracellular localization of GFP-SV5-V is shown in the lower 
panels.  
 
This is consistent with both proteins interacting in HeLa cells. Moreover, SV5-V was 
able to increase accumulation of an N-terminal GFP variant of DDB1 in the nucleus 
(data not shown) as reported for DDB2 but not for HBx [85]. We next compared the 
DDB1-binding properties of SV5-V and HBx. Publication 2 shows using a yeast two-
hybrid protein interaction assay that HBx and SV5-V interact with DDB1 at 
overlapping binding sites. We also demonstrated by co-immunoprecipitation studies 
that both viral proteins can disrupt the UV-DDB complex. We next asked whether in 
mammalian cells an excess of SV5-V would interfere with the binding of HBx to 
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limiting amounts of DDB1. Whole cell extracts were prepared, HA-DDB1 was 
immunoprecipitated and proteins bound to DDB1 were detected by Western Blot 
analysis. The excess of myc-SV5-V strongly reduced the amount of myc-HBx that 
coimmunoprecipitated with HA-DDB1 (Figure S6). These results demonstrated that 
both viral proteins also exhibit a mutually exclusive binding in mammalian cells, and 
provide direct evidence that SV5-V prevents HBx from inducing cell death by 
displacing it from DDB1 (Publication 2 Figure. 3) 
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Figure S6: SV5-V interferes with HBx-DDB1 complex formation 
 
Shown are results of coimmunoprecipitation experiments with extracts from transiently transfected 
HeLa cells. N-terminally epitope-tagged HA-DDB1, myc- HBx and myc- SV5-V produced from the 
expression vector pSRaS were transfected at a 1:2:9 DNA ratio in pairwise combination or all three 
together. Whole cell extracts were prepared 1 day after transfection and subjected to 
immunoprecipitation with a Mab against the HA epitope. The immunoprecipitates were separated by 
SDS-PAGE and analyzed by Western blot assays with anti-HA and anti-myc antibodies.  
 
4.2.3 IFN signaling 
 
Despite strikingly similar DDB1-binding properties, HBx has the potential to interfere 
with cell viability in culture whereas SV5-V does not.  SV5-V and the V protein of 
human parainfluenza virus 2 (hPIV2), which also binds DDB1, exhibit the ability to 
block interferon (IFN) signalling by specifically targeting STAT1 or STAT2, 
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respectively, for proteasome-mediated degradation. Viruses often adopt strategies of 
immune evasion by interfering with the action of host cellular proteins that are 
important components of the immune response, like the interferon signalling. We 
therefore asked whether HBx could provide the same activity than the V proteins of 
the paramyxoviruses. In collaboration with D. Garcin, we performed an IFN α/β 
responsive reporter gene assay. The plasmid pISRE-luc (a luciferase reporter plasmid 
containing a basal promoter with a tandemized ISRE) was transfected together with 
HBx, SV5-V or DDB2, and luciferase activity was assessed with or without IFN-α 
treatment. As previously described [170] expression of SV5-V blocked IFN 
responsive luciferase activity, whereas HBx or DDB2 expression had no effect on 
IFN signalling (Figure S7). Consistent with these results Western Blot analysis 
revealed that HBx does not induce any degradation of STAT1 nor STAT2 (data not 
shown). HBx therefore lacks this particular anti-interferon signalling activity but most 
certainly the hepatitis B virus has developed other immune evasion strategies.  
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Figure S7: HBx does not inhibit IFN signaling 
 
IFN-α responsive 2fTGH cells were transfected with the pISRE(firefly)luc and the pTK(renilla) luc 
reporter constructs, and the indicated plasmids. At 24 posttransfection, the cells were treated or not 
with 1,000 IU of recombinant IFN- α 2/ α 1 per ml. At 14 h after IFN treatment, cells were harvested 
and assayed for firefly and renilla luciferase activity. Relative expression levels were calculated by 
dividing the firefly luciferase values by the renilla luciferase values.  
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4.3 Study of DDB1 function using new tools 
 
4.3.1 Creation of siRNA-tools 
 
The technique of RNA interference (RNAi), originally described for gene silencing in 
the nematode C.elegans, has recently been extended to mammalian cells. Refinements 
of this technology permit the long-term silencing of genes by expression of small 
interfering RNA-like transcripts from the H1-RNA gene promoter. Since no DDB1 
mutant cell lines are available, this technique will be used to knockdown DDB1 and 
assess the consequences of DDB1 depletion on cell cycle regulation or HBx 
functions. The silencing cassette derived from pSUPER (kindly provided by 
R.Bernards) was cloned both into an episomal Epstein-Barr virus-based vector 
bearing a resistance-conferring gene and into a lentiviral vector. Studies in HeLa cells 
will mainly use episomal vectors since high transfection efficiencies and selection 
procedures are available. As lentiviral vectors can stably transduce a wide variety of 
poorly transfectable cell lines, we will use this system for studies in the HepG2 cell 
line. Using this approach, we successfully showed that DDB1 is essential for SV5-V-
mediated STAT1 degradation (Publication 2 Figure 5.) 
The ability to generate cells in culture that lack DDB1 by RNAi does also provide a 
means to assess the function of transfected DDB1 mutants on a null background.  This 
can be done by introducing a number of silent mutations into the complementary 
DNA region of DDB1 cDNA. The mismatches abolish pairing of the short RNAs with 
the mutant DDB1 mRNA, so the mRNA encoding the mutant protein will not be 
eliminated. This approach is also one of the two strategies available to test whether 
the effect of a siRNA is due to specific silencing of the intended target. The other 
strategy consists in rescuing by combining wild-type cDNA with siRNA to the 3' 
untranslated region, which differs between the endogenous and the ectopic version of 
the protein [180]. The RNAi technique provides a complementary approach to the 
knockout of the gene in the mouse system, and has the advantage that it can be 
applied to human hepatoma cell line. The role of DDB1 or any other protein of 
interest in the viral replication cycle could be assessed. 
In an attempt to test for the specificity of the siRNA against DDB1 and to develop 
tools for assessing the functionality of various DDB1 mutants a non-siRNA 
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susceptible DDB1 cDNA version (nsi-DDB1) was designed. For this purpose, a 
cDNA clone was constructed that contains silent mutations introduced at the third 
position of three adjacent codons. These mismatches should prevent the siRNA-
DDB1 from hybridizing to and degrading the ectopically expressed DDB1 mRNA, 
whereas the endogenous DDB1 messenger should be depleted. When tested in the 
yeast two-hybrid protein assay, the nsi-DDB1 construct was, as expected, encoding a 
protein able to normally interact with HBx and SV5-V (data not shown). Western blot 
and flow cytometry analyses of HeLa cells transfected with the relevant constructs 
showed that only the wild-type GFP-DDB1 was depleted upon cotransfection of 
siRNA-DDB1 plasmid, whereas the nsi-GFP-DDB1 version was not affected (Figure 
S9A). These experiments demonstrate the specificity of the silencing against DDB1 
and furthermore provided a mean to rescue the effect of the siRNA. 
 
4.3.2 Study of various DDB1-mediated functions  
vect DDB1-siRNA
 
Figure S8: Long-term silencing of DDB1 causes cell morphology alterations 
 
HeLa cells were transfected with an episomal vector producing a DDB1-specific siRNA and bearing an 
hygromycin-resistance gene. Drug resistant cells were stained at day 10 post-transfection with an anti-
tubulin antibody.  
 
The long-term knockdown of endogenous DDB1 (data not shown; Publication 2 
Figure 5) in HeLa cells produces a significant alteration in cell morphology usually 
starting between day 8 and 10. The cells are mainly binucleated and displayed an 
abnormal tubulin network, resembling early HBx-expressing cells (Figure S8). 
However, cells with decreased levels of DDB1 exhibited an increased number in 4N 
DNA content as assessed by propidium iodide staining, but almost never displayed a 
more than 4N DNA content (data not shown). When tested in the colony formation 
assay, depletion of DDB1 clearly showed interference with cell viability (Figure 
S9B). 
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These observations are consistent with the phenotype of the S.pombe deletion of the 
Ddb1 gene [167-169]. The Ddb1∆ strain displayed elongated cell phenotype and 
abnormal nuclei with unequal DNA distribution, arguing in favor of a defect in 
chromosomal segregation. More recently, Ddb1 was found to be involved in S phase 
progression and in control of the replication checkpoint. Our collaborators at the 
ISREC, V.Simanis (S.pombe) and P.Gönczy (C.elegans) also pointed to a problem in 
DNA replication in their respective knockouts.  The phenotype induced by depletion 
of DDB1 in mammalian cells clearly needs further investigations, for example by 
using tools developed for the analysis of the HBx-mediated phenotype. 
 
Complementation studies with a non-siRNA susceptible version of DDB1 were 
performed in the case of SV5-V mediated degradation of STAT1 and in the DDB1 
depletion-induced phenotype. Cotransfection of a non-siRNA-susceptible DDB1 
restored viability to cells depleted of DDB1 (Figure S9B). The rescued cells grew 
similarly to normal cells and the morphological changes were almost undetectable. 
We previously showed that SV5-V is less competent in inducing degradation of 
STAT1 in the DDB1 knockdown cells (Publication 2 Figure 5). It is important to 
emphasize that these experiments were performed at a stage where no significant 
morphological changes due to DDB1 depletion could be observed. Complementation 
with a non-siRNA susceptible version of DDB1 allowed SV5-V mediated STAT1 
degradation to be optimal again (compare lane 6 and 8 in Figure S9C). Overall these 
studies provide a new strategy to test different DDB1 mutants for their ability to carry 
out essential function for cell viability and for SV5-V mediated STAT1 degradation. 
In addition, these mutants could be tested for their ability to interact with SV5-V 
or/and HBx and to mediate cytotoxicity when fused to HBx. The identification of the 
different functional domains of DDB1, a protein with increasing fame, could be 
achieved with these studies. 
 
We found that DDB1 is particularly sensitive to both terminal and internal deletions 
(data not shown), thus precluding us from carrying out a structure-function analysis of 
DDB1 using deletion mutants. To identify functionally important regions within the 
1140 amino acids long DDB1 protein, an in vitro random insertion mutagenesis 
strategy would be more suitable. Additionally, we tried using the yeast two-hybrid 
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assay to isolate suppressor mutations in DDB1 that would compensate for the 
disruptive mutations in HBx. A library of DDB1 mutants bearing amino acid 
substitutions was generated by UV mutagenesis and assessed for interaction with the 
functionally defective HBx(R96E) mutant. Unfortunately, we failed to isolate any 
suppressor mutant. More efficient mutagenesis (mutagenic PCR) restricted to the 
segment of DDB1 that is required for interaction with HBx will be performed in the 
future. The imminent characterization of the crystal structure of DDB1 (see 
introduction) would be of high interest for these studies. The availability of such 
mutants would provide a powerful tool to assess the relevance of an interaction 
between HBx and DDB1 for viral infection using an animal model. 
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Figure S9: A non-siRNA susceptible DDB1 complements the defects induced by 
DDB1 depletion. 
 
A) Wild type GFP-tagged DDB1 and non siRNA susceptible variant were cotransfected with a vector 
expressing the siRNA against DDB1 (lower part) or a control vector (upper part) into HeLa cells. GFP 
fluorescence was assessed 3 days after transfection by FACS. 
B) HeLa cells were cotransfected with wild type or a non siRNA susceptible version of DDB1 
expressing plasmids and either control vector (-) or a construct (+) that directs the synthesis of a 
DDB1-specific siRNA. A GFP gene was cotransfected to assess for comparable transfection 
efficiencies by FACS analysis. Double selection with hygromycin and blasticidin was performed and 
drug resistant cells were stained with crystal violet at day 12 post-transfection. 
C) The same cells as in B) were subjected to whole cell extract preparation and separated on SDS-
PAGE at day 8 after transfection. DDB1, STAT1 and GFP-SV5-V were detected by Western blotting 
with specific antibodies.  
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 4.3.3 Perspectives: role of cullin-4A in HBx activity 
 
The SV5-V protein targets STAT1 for proteasome-mediated degradation by a 
mechanism that requires DDB1 and cullin-4A, a member of the cullin family of 
proteins that act as scaffolds for the assembly of E3 ubiquitin ligase complexes. This 
suggests that HBx may affect cell viability by targeting some proteins for ubiquitin-
dependant proteolysis through its interaction with DDB1, an activity that would 
implicate cullin-4A. To test whether cullin-4A is implicated in HBx activity, we used 
RNAi technique to decrease its expression and also co-immunoprecipitation studies to 
assess whether HBx is part of an E3 ubiquitin ligase complex.  
By RNA-directed gene silencing, we succeeded in decreasing both endogenous and 
Flag-tagged human cullin-4A (Figure S10A). However, silencing was less effective 
than for DDB1.  Under these conditions, inhibition of cullin-4A expression did not 
protect STAT1 from degradation induced by SV5-V, whereas others did report a 
partial STAT1 protection [142]. Silencing of cullin-4A exhibited a slight effect on 
HBx-mediated toxicity reflected by the fact that the mitotic defects seemed delayed 
and by a reduced number of cells showing altered morphology (data not shown). 
Further studies will need more effective silencing constructs and targeting both cullin-
4A and 4B to exclude functional redundancy problems. 
Until now, we failed to obtain evidence that HBx or SV5-V form a ternary complex 
with DDB1 and cullin-4A although such a complex has been reported for SV5-V. 
However, we could show binding of a myc-tagged mouse cullin-4A to endogenous 
DDB1 (Figure S10B). This will allow us to test whether HBx and cullin-4A are 
bridged together by binding to DDB1.  The mouse cullin-4A also provides a non-
siRNA susceptible version of cullin-4A to test for specificity of the silencing. The 
implication of cullin-4A in the different activities of HBx clearly needs further 
investigations. 
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Figure S10: Tools to assess cullin-4A involvement in HBx-mediated cell death 
 
A) Depletion of cullin-4A 
HeLa cells were transfected with an episomal vector producing a cullin-4A-specific siRNA (+) or a 
control vector (-). Levels of endogenous cullin-4A (6 days in selection) or ectopic Flag-tagged cullin-
4A (2 days post-transfection) were assessed in these cells. Western blot analysis was performed on 
whole cell extracts separated by SDS-PAGE and revealed by anti-cullin-4A or anti-Flag specific 
antibodies. Arrowhead represents unspecific bands whereas arrow shows the respective cullin-4A 
versions.  
B) DDB1 interacts with cullin-4A 
Myc-mouse cullin-4A transfected HeLa cells were subjected at day 1 after transfection to 
immunoprecipitation with an antibody against the myc epitope. The immunoprecipitates were 
separated by SDS-PAGE and analyzed by Western blot for the presence of the endogenous DDB1.  
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 4.4 Hepatitis B virus X protein stimulates viral genome replication in 
a DDB1-dependent manner via a pathway distinct from that leading 
to cell death 
 
4.4.1 Publication 3: Manuscript in preparation 
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ABSTRACT 
 
The HBx protein of hepatitis B virus (HBV) is essential for virus infection and has 
been implicated in the development of liver cancer associated with chronic infection, 
but the underlying mechanisms remain unknown. HBx can interact with a number of 
unrelated cellular proteins and in cell culture it exhibits pleiotropic activities, among 
which is the ability to interfere with normal cell viability and stimulate HBV 
replication. Previous work has demonstrated that HBx affects cell viability by binding 
to DDB1, a highly conserved protein recently found to assemble into a complex 
displaying E3 ligase activity. Here we show that an interaction with DDB1 is also 
needed for HBx to stimulate HBV genome replication. Thus, HBx point mutants 
defective for DDB1-binding fail to promote high level of replication of an HBx-
deficient HBV genome when provided in trans, and one such mutant regains activity 
when directly fused to DDB1. Furthermore, DDB1 depletion by RNA interference 
compromises replication of wild-type HBV genome indicating that HBx expressed 
from the viral genome also functions in a DDB1-dependent fashion. We also show 
that HBx in association with DDB1 acts in the nucleus and stimulates HBV 
replication mainly by enhancing viral mRNA levels, regardless of whether it is 
expressed from its own viral genome or provided in trans by cotransfection of an HBx 
expression plasmid. Interestingly, despite displaying identical requirements with 
respect to DDB1 binding, HBx appears to stimulate viral genome replication via a 
pathway distinct from that leading to cell death. 
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INTRODUCTION 
 
Hepatitis B virus is the prototype of the hepadnaviridae, a family of small 
hepatotropic enveloped viruses. HBV is a major causative agent of liver diseases. The 
HBV genome, the smallest among mammalian viruses, consists of a partially double-
stranded 3.2 kb DNA with four major open reading frame (ORFs). Viral replication 
occurs within viral capsids (core particles) in the cytoplasm of virus producer cells. 
Virally encoded polymerase uses a pregenomic RNA template to synthesize viral 
DNA by reverse transcription. 
The smallest of the four HBV ORFs encodes for the regulatory protein HBx. In 
woodchuck hepatitis virus, the X protein is essential for viral replication 5,30. In 
human hepatoma cell lines, HBV genome replication is significantly dependent on 
expression of HBx 19. However the exact role of this protein in viral replication 
remains to be determined. 
DDB1, a protein highly conserved during evolution, is one of the best-characterized 
interactors of HBx 14,16,25. DDB1 is the 127-kDa subunit of the UV-DDB complex 
implicated in nucleotide excision repair 12. The recently described presence of DDB1 
in complexes displaying E3 ligase activity 11,27suggests that it may be involved in 
targeting specific proteins for ubiquitin-dependant proteolysis. 
Binding of HBx to DDB1 is essential for HBx to activate transcription and to induce 
cell death 16,25. In earlier studies, we have shown that the ability of HBx to interfere 
with cell viability requires association with DDB1 in the nuclear compartment 1. The 
cytotoxic activity is DDB2-independent and specific to the HBx-DDB1 complex since 
simian virus 5 V protein exhibits similar DDB1 binding properties yet lacks this 
activity 15. Binding to DDB1 is a conserved feature among the mammalian X proteins, 
and evidence has been presented for a critical role of this interaction in efficient 
woodchuck hepatitis virus infection 25.  
In this study, we used the HBx-dependant HepG2 cell HBV replication system to 
show that HBx-mediated stimulation of HBV replication requires the formation of the 
HBx-DDB1 complex. Interaction through their natural binding regions and 
appropriate levels of DDB1 are required for the HBx-DDB1 complex to achieve 
proper HBV replication.  The stimulatory function of HBx on HBV replication 
depicts the same DDB1-dependant binding properties than the previously reported 
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HBx-mediated cytotoxic activity. Yet both HBx-mediated activities may involve 
different pathways at some point after the initial DDB1-HBx interaction.  
 
 
MATERIALS AND METHODS  
 
Plasmid and Lentivirus vectors 
 
All recombinant DNA work was carried out according to standard procedures. The 
mammalian HBx expression plasmids 1,15,16, the wild-type (payw1.2) and HBx-
deficient (payw*7) HBV plasmids used in this study have been described 19. The 
HBV plasmids represent a greater-than-unit-length DNA of the viral genome in which 
transcription of all viral RNAs is under the control of HBV-specific transcriptional 
elements. The [HBV HBx(-)] plasmid contains an ochre termination signal after 
codon 7 in the HBx ORF. 
 
To allow lentiviral-mediated delivery of the DDB1-specific siRNA, the H1-siRNA 
cassette was excised from pSUPER-DDB1 15 and introduced into the pLV-TH 
vector28. Additional constructs expressing GFP-HBx and GFP-HBx(R96E) from the 
pWPT lentiviral vector were performed 31. All recombinant lentiviruses were 
produced by transient transfection of 293T cells according to standard protocols 31. 
Briefly subconfluent 293T cells were cotransfected with 20 µg of plasmid vector, 15 
µg of pCMV-∆R8.91, and 5 µg of pMD2G-VSVG by calcium phosphate 
precipitation. After 16h medium was changed and recombinant lentivirus vectors 
were harvested 24h later. 
 
 
Cell culture, transduction and transfection 
 
HeG2 and Huh7 cells were grown at 37°C in the presence of 5% CO2 in modified 
Eagle's medium (Invitrogen) supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine, 1 mM Sodium pyruvate, 1x non-essential amino 
acids and 10% v/v fetal calf serum (Chemie Brunschwig). HeLa, and 293T were 
grown in the same conditions except for the use of Dulbecco's modified Eagle's 
medium. 
For transduction, the cells were plated and after 16h medium containing recombinant 
lentivirus vectors was added. Following 24h of incubation, the cells were washed, 
split and analyzed 2 days later by fluorescence-activated cell sorting (FACS). The 
conditions used allowed to obtain a transduction efficiency as high as 97-99%. The 
cells were then either analyzed for the interference with cell viability by colony 
formation assay (in the case of pWPTS-GFPHBx variants transduction) or transfected 
for subsequent HBV-replication studies (in the case of pLV-THsiDDB1transduction). 
The hepatoma cells that had been plated the previous day on collagen-coated or 
normal dishes were transfected using the FuGENE 6 reagent (Roche) according to the 
manufacturer's instructions. An expression plasmid for GFP or RFP was cotransfected 
to assess for transfection efficiencies by fluorescence-activated cell sorting (FACS). 
Three days post-transfection cells were assessed for viral replication and transcription. 
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Analysis of replication and transcription 
 
Cells were cotransfected with the wild-type or HBx-deficient [HBV HBx(-)] HBV 
plasmids and a HBx-variant expressing plasmid. After 24 h postransfection, cells 
were trypsinized, analyzed by fluorescence-activated cell sorting (FACS) and replated 
for Southern blot analysis of core-associated DNA or Northern Blot analysis of total 
RNA, two days later. For Northern blot RNA hybridization, total RNA was extracted 
from cells by Trizol reagent (Invitrogen), equal amounts loaded on an agarose-
formaldehyde gel and transferred to Hybond N+ membrane (Amersham). Viral 
replication was assessed by purification of cytoplasmic core particles as previously 
described, and DNA was analyzed by Southern blotting (Scaglioni PP J.virol 71:345; 
Melegari J. Virol. 72:1737). Radioactively 32P-labeled probes were generated by 
using the Redi-prime labeling kit (Amersham) and an HBV genome-length DNA 
fragment. All assays were performed at least three times with comparable results. 
Some experiments were quantified by phosphoimager and Quantity One software or 
by real-time PCR using HBV pol-specific primers 26. 
 
 
RESULTS 
 
Stimulation of HBV replication correlates with the formation of the DDB1-HBx 
complex 
We previously showed that HBx interferes with cell viability through interaction with 
the DDB1 protein. To assess the role of the HBx-DDB1 interaction in HBV 
replication, we made use of an HBx-dependent HBV replication system in tissue 
culture in which the HBx function can be provided in trans. Human hepatoma HepG2 
cells were transfected with equivalent amounts of either a wild-type HBV genome 
(HBV) or an HBx-deficient HBV genome (HBV(∆HBx)) harboring a translational 
termination signal after codon 7 in the HBx ORF (kindly provided by R.J. Schneider 
and colleagues, New York, USA), with or without cotransfection of an HBx 
expression plasmid. Three days later, cytoplasmic viral core particles were purified 
and the amount of viral DNA replicative intermediates was assessed by Southern blot 
hybridization of extracted DNA.  
The absence of HBx expression significantly reduced HBV DNA replication. 
Replication of the HBx-deficient HBV genome was restored to the wild-type level by 
cotransfection of an HBx expression plasmid, but not by the HBx(R96E) point mutant 
which we believe is selectively defective for DDB1-binding (left panel in Fig. 1A). 
The HBx(R96E) point mutant was previously shown to be unable to interact with 
DDB1 and, as a result, lacks cytotoxic activities 16. Cotransfection of wild-type HBx 
or HBx(R96E) had no effect on replication of the wild-type genome (right panel in 
Fig. 1A), indicating that the amount of HBx produced from the viral template suffices 
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for HBx to fully exert its stimulatory effect, and that HBx(R96E) has no dominant-
negative effect. 
To further extend the correlation between DDB1-binding and stimulation of viral 
replication, we analyzed a series of HBx point mutants bearing amino substitutions 
within the central minimal DDB1-binding region 16 that were tested previously for 
DDB1-binding and cytotoxic activities. As shown in Figure 1B, in addition to 
HBx(R96E) two other mutants, HBx(K95A/R96A) and HBx(L98F), displayed a 
compromised ability to stimulate HBV replication. These mutants were previously 
shown to be defective for DDB1-binding and cytotoxic activities. By contrast, the 
DDB1-binding proficient HBx(K91E), HBx(K95E) and HBx(D107R), active in 
interference with cell viability showed restoration of HBV replication, whereas 
mutant HBx(K113E; D114R) showed an intermediate phenotype as reported 
previously for cytotoxic activities. Mutant HBx(R77E/R78E) did also have reduced 
activity in the replication assay but was previously shown to possess strong cytotoxic 
activities. This mutant may therefore be compromised in a specific function important 
for replication other than DDB1 binding. We also tested an amino-terminal truncation 
of HBx lacking the first 44 amino acids, which are required for HBx dimerization 17 
and oncogenic properties 10, and found that it behaves like wild type HBx in all 
respects (data not shown). Indeed, this HBx variant which was able to induce cell 
death was also complementing the replication levels of the HBx-defective HBV 
genome (data not shown). Collectively our results suggest that the interaction between 
HBx and DDB1 is important for both HBx-mediated activities: interference with cell 
viability and stimulation of HBV replication. 
We next investigated whether HBx acts as a complex with DDB1 to achieve 
stimulation of viral replication as reported for induction of cell death. The defect in 
the HBx(R96E) mutant is specifically caused by its inability to efficiently interact 
with DDB1. We previously showed that this mutant which cannot interact with the 
endogenous DDB1 regains its cytotoxicity when covalently fused to DDB1 15.  
Additionally we showed that further compromising the interaction by fusing the 
DDB1(i947) variant that specifically lacks HBx-binding abilities fails to restore 
activity to HBx(R96E). When tested in the context of HBV replication, a covalent 
link between HBx(R96E) and DDB1 allowed for complementation of the DNA 
replication levels whereas fusion to the DDB1(i947) was almost ineffective (Fig. 1C). 
This suggests that a covalent link between HBx and DDB1 does not bypass the need 
for an interaction between the two proteins for proper stimulation of HBV replication. 
Furthermore DDB1 and HBx must interact through their natural binding sites to 
achieve their function in HBV replication. 
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DDB1 depletion impairs stimulation of replication by HBx  
To directly assess the role of DDB1 in HBx-mediated stimulation of HBV replication, 
we inhibited DDB1 gene expression by RNA interference. Cells were transduced with 
a lentiviral vector directing synthesis of a siRNA against DDB1 prior to transfection 
of the different HBV genomes. The level of replication of wild-type HBV was found 
to be substantially reduced in siRNA treated cells, whereas the HBx-deficient HBV 
remains unaffected (Fig. 2). These results show that HBx expressed from the genome 
needs the presence of DDB1 to exert its biological effect on viral replication. Thus, 
DDB1 was essential for HBx-mediated stimulation of viral replication. An excess of 
DDB1 was not able to overcome the defect in replication exhibited by the HBx-
defective HBV genome (data not shown), suggesting that HBx interacts with DDB1 
to perform a specific function and not only to stabilize the DDB1 levels. Appropriate 
levels of DDB1 are required to allow the binding of HBx to DDB1 and the 
concomitant stimulation of viral replication.  
 
HBx acts in the nucleus and stimulates the amounts of HBV transcripts  
HBx localizes in both the cytoplasm and the nucleus. To determine in which 
subcellular compartment HBx promotes viral replication, we made us of previously 
described NLS-HBx and NES-HBx variants 1 on the amount of viral DNA replicative 
intermediates. We previously showed that HBx retains DDB1-binding-dependant 
cytotoxic activities when engineered to accumulate in the nucleus but not when 
excluded from the nucleus. The NES-HBx engineered to be cytoplasmic was only 
weakly able to complement the defect in replication observed for the HBx-defective 
HBV genome (Fig. 3A). On the other hand the strictly nuclear NLS-HBx was able to 
restore levels of replication as efficiently as wild-type HBx. These results point to the 
nuclear fraction of wild-type HBx as being responsible for promoting HBV 
replication and suggest that HBx expressed in its native context from the HBV 
genome exhibits most of its activity in the nucleus. 
To determine which step of the replication pathway is stimulated by HBx, we 
examined the dependence of viral transcription on HBx. For this purpose, we 
extracted total RNA from the transfected cells and analyzed the steady-state levels of 
viral mRNAs by Northern blot analysis. The HBx-mediated increase in the level of 
HBV replication intermediates is associated with a similar increase in the levels of 
viral mRNAs (Fig. 3B). All mRNAs species are augmented to approximately the 
same extend both when the HBV genome itself is used as the source of HBx protein 
or when HBx is supplemented in trans. The wild-type HBx could complement the 
 110
decreased amount of viral RNAs expressed by the HBx-defective HBV genome 
whereas the DDB1-binding defective HBx(R96E) was unable to restore viral RNA 
levels (Fig. 3B). The same activity dependant on HBx binding to DDB1 was observed 
when smaller amounts of HBV genomic DNA were used for transfection. Our data 
suggest that the interaction between HBx and DDB1 increases the abundance of HBV 
mRNAs. 
 
The pathway leading to HBx-mediated stimulation of HBV replication is distinct from 
that leading to cell death 
The results presented thus far show that the requirements with respect to DDB1 for 
HBx to promote HBV replication are identical to those needed for HBx to interfere 
with normal cell growth, suggesting a direct functional link. However, HBx has no 
effect on HBV replication in the hepatoma cell line Huh7 (Fig. 4A). No differences 
were detected in the levels of viral replication between wild type and HBx-deficient 
HBV genomes. Lack of HBx expression leads to decreased HBV replication only in 
the HepG2 cell line, not in the Huh-7 cell line, as reported previously 19,29. Yet both 
cell lines express DDB1, and HBx but not the HBx(R96E) mutant is toxic in both cell 
lines as assessed by colony formation assay (Fig. 4B). Interestingly, despite 
displaying identical requirements with respect to DDB1 binding, HBx appears to 
stimulate viral genome replication via a pathway distinct from that leading to cell 
death. 
 
DISCUSSION 
 
HBx can interact with a number of unrelated cellular proteins and in cell culture it 
exhibits pleiotropic activities, including inhibition of cell growth and stimulation of 
HBV replication. In previous studies (inhibition of cell growth) 1,15,16 and here 
(stimulation of HBV replication), we show that both of these activities require the 
binding of HBx to DDB1. The stimulatory function of HBx on viral genome 
replication exhibits the same DDB1-dependant binding properties than the previously 
described HBx-mediated cytotoxic activity. Formation of the HBx-DDB1 and 
interaction through their natural binding regions are required both HBx-mediated 
activities. The nuclear fraction of HBx, acting predominantly on the amounts of viral 
mRNAs in the case of HBV replication studies, is responsible for these effects. 
Despite these common features, cytotoxic and HBV replication-promoting activities 
may involve different pathways at some point after the initial DDB1-HBx interaction.  
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Evidence has been presented for a critical role of this interaction in efficient 
woodchuck hepatitis virus (WHV) infection arguing for a conserved role of the X-
DDB1 complex in mammalian heapdnavirus replication 23.  However, when tested in 
vitro, WHV genomes carrying WHx mutations that markedly alter DDB1 binding are 
functional but most likely only for the first minus strand DNA synthesis. The in vitro 
system used to assess WHV replication in human HepG2 cells might probably not 
allow all viral DNA replicative intermediates to occur and could thereby explain the 
discrepancy with our results. Indeed in our study, the profile of viral DNA replicative 
intermediates species exhibited by the HBx-deficient HBV genome is mostly similar 
to that shown by the wild-type HBV genome but in markedly decreased amounts. 
Efficient virus replication, in the context of natural animal infection or in our human 
HBV based system, might perhaps require X to overcome an otherwise limiting step 
such as appropriate viral transcription level required to efficiently complete 
replication. Here, we provide the first evidence for a functional role of the HBx-
DDB1 interaction in the replication of the human hepatitis B virus.  
Recent studies 3,13 reported that HBx stimulates HBV DNA replication by enhancing 
the reverse transcription activity of the viral polymerase while having little effects on 
viral mRNA steady-state levels 2,3. In marked contrast, we found that HBx promotes 
HBV replication by acting predominantly, if not exclusively, on the viral mRNA 
levels, regardless of whether it is expressed from its own viral genome or from a 
recombinant vector. This discrepancy is not easily explainable, since the same HBV 
genomic constructs and recipient HepG2 cell line were used in both studies. One 
possibility is that HBx can mediate different activities depending on the growth 
conditions of the cells. It would be interesting to see if HBx effect on the viral 
polymerase does also requires its interaction with DDB1.  
We showed that the nuclear fraction of HBx is responsible for promoting HBV 
replication. However, we do not know by which mechanism HBx stimulates the 
amounts of HBV transcripts upon binding to DDB1. HBx is widely recognized to 
display the ability to stimulate transcription of a variety of enhancers and promoters. 
Some of these transactivation activities require binding to DDB1 24. The association 
of STAGA, a chromatin-acetylating transcription coactivator, with DDB1 could 
perhaps facilitate transactivation by acting on chromatin accessibility 18. Concerning 
HBV specific regulatory elements, HBx produced from the HBV genome has been 
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shown to activate HBV promoters and enhancers both in Huh7 6 and in HepG2 cells 
20. Consistent with our results showing a nuclear viral replication promoting activity 
of HBx, HBV enhancer I has been reported to be stimulated by HBx through a 
pathway that involves a nuclear function of HBx 8. In our studies, Huh7 cells that bear 
a mutated p53 gene 4 and in which HBx has no stimulatory effect on HBV replication, 
the replication levels of the HBx-deficient HBV genome are comparable to those 
observed for the wild-type genome in HepG2 cells, which contain wild-type p53. 
These results suggest that HBx may act by relieving an inhibitory activity. Indeed, it 
has been reported that p53 can repress HBV transcription by binding specifically to 
the HBV enhancer I, and that HBx can prevent p53 from exerting this repressive 
effect 7,21. However, under our experimental conditions we observed no significant 
effect on HBV replication, upon cotransfection of a wild-type p53 expression 
construct in Huh-7 cells, or siRNA-mediated down-regulation of endogenous p53 
expression in HepG2 cells (data not shown). These data suggest that the HBx-
mediated stimulation of HBV replication as well as the HBx-induced cytotoxicity 
(data not shown) do not depend on the p53 status of the cells. 
Additional experiments showed that transfection of hepatoma cell lines with the wild-
type HBV genome but not with the HBx-deficient HBV genome leads to interference 
with cell viability as assessed by colony formation assay (data not shown). The 
finding that when expressed from its own viral genome HBx affects the viability of 
hepatoma cell lines is rather unexpected, since HBV does not exhibit cytopathic 
effects other than those caused by immunological reactions. Consistent with our data, 
physiological HBx expression from constructs competent for HBV replication has 
been shown to induce supernumerary centrosomes or apoptosis 9,22. An interesting 
possibility is that HBx exhibits deleterious activities only in actively dividing cells but 
not in quiescent cells, and experiments aimed at addressing this issue are ongoing. 
According to this hypothesis, HBx would manifest no deleterious activities at the time 
of infection when most hepatocytes are in a quiescent state, but it would do so at later 
stages of the infection when hepatocytes divide to replace those destroyed by the host 
immune response. 
Although future studies are needed to unravel the detailed HBx mechanism of action, 
our work defines the HBx-DDB1 interaction as a potential target of anti-hepatitis B 
virus drugs. 
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FIG. 1. Stimulation of HBV replication requires the formation of the HBx-DDB1 
complex.  
 
Cytoplasmic HBV capsids were isolated from equal numbers of HepG2 cells three 
days after cotransfection with wild-type HBV or HBV(∆HBx) genomic DNA and 
equal amounts of empty vector (+ vect) or derivatives expressing the indicated HBx 
proteins. Transfection efficiencies were similar for the different constructs based on 
FACS analysis of cotransfected GFP reporter. Southern blot DNA analysis of HBV 
DNA replicative intermediates in cytoplasmic core particles is shown. Hybridization 
was performed with 32P-labeled probes prepared from full length HBV genomic 
DNA. Blots were visualized by autoradiography and quantified by densitometry. Each 
panel (A), (B) and (C) is representative of at least three independent experiments. 
Since DDB1-binding defective and proficient HBx mutants were previously shown to 
accumulate to similar protein levels, difference in the complementation of the HBx-
defective HBV genome were not due to different stability of the HBx mutant proteins.  
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FIG. 2. HBx-mediated stimulation of HBV replication is less efficient in cells 
expressing reduced amounts of DDB1. 
 
HepG2 cells were transduced with a siRNA lentiviral vector against DDB1 (+) or a 
control vector (-). Transduction efficiencies were similar for the different constructs 
based on FACS analysis of GFP reporter. Four days after transduction, the cells were 
transfected with wild-type HBV or HBV(∆HBx) genomic DNA and assessed for core 
particle-associated HBV DNA as described for Figure 1. Results from one of two 
independent experiments are shown.  
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 FIG. 3. HBx functions in the nucleus and acts mostly on HBV mRNAs levels. 
 
(A) HepG2 cells were cotransfected with wild-type HBV or HBV(∆HBx) genomic 
DNA and equal amounts of empty vector (+ vect) or derivatives expressing the 
indicated HBx proteins. Core particle-associated HBV DNA was assessed as 
described for Figure 1. Results are representative of at least three independent 
experiments. 
(B) Northern blot analysis of total RNA extracted from cells and Southern blot DNA 
analysis of HBV DNA replicative intermediates in cytoplasmic core particles are 
shown from the same initial transfection experiment. Results were quantified by 
densitometry and levels obtained for cells transfected with wild-type HBV genome 
was set to 100%. Values are representative of one of three independent experiments. 
Viral RNA levels were normalized to b-actin controls.  
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 FIG. 4. Both HBx-mediated activities display identical requirements with 
respect to DDB1 binding, yet distinct pathway are involved. 
 
(A) In contrast to HepG2 cells, no differences were detected in the levels of viral 
replication between wild type and HBx-deficient HBV genomes in Huh7 cells. The 
amount of HBV replication intermediate shown is normalized to transfection 
efficiency. 
(B) HeLa, Huh7 and HepG2 cells were transduced with a lentiviral vector expressing 
GFP-HBx or GFP-HBx(R96E). Transduction efficiencies were similar for the 
different constructs based on FACS analysis of GFP reporter. Surviving cells were 
stained with crystal violet 16 days after transduction. The lower panels show the 
amount of endogenous DDB1 present in whole cell extracts preparation and detected 
by Western blotting.  
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4.4.2 HBx expressed in its most native context interferes with cell viability 
 
To determine whether the induction of cell death by ectopic expression of HBx has 
any physiological relevance, we analyzed this cytotoxic activity in HepG2 cells 
transfected with replication-competent wild-type HBV DNA or an HBx-deficient 
HBV DNA. We observed interference with cell viability in cells expressing HBx from 
its own genome, but not in cells lacking expression of HBx, as assessed by colony 
formation assay (Figure S11). Microscopic analysis revealed that HBx expressed in 
the context of its whole genome exhibits the same ability to induce multinucleated 
cells followed by cell death, than HBx expressed from a recombinant vector. The 
finding that when expressed from its own viral genome HBx affects the viability of 
hepatoma cell lines is rather unexpected, since HBV does not exhibit cytopathic 
effects other than those caused by immunological reactions. However, our data are in 
agreement with previous reports showing that physiological HBx expression from 
constructs competent for HBV replication affects the cell viability by inducing 
supernumerary centrosomes or apoptosis [101; 114]. An interesting possibility is that 
HBx exhibits deleterious activities only in actively dividing cells but not in quiescent 
cells, and experiments aimed at addressing this issue are presented below. At the time 
of infection hepatocytes are in a quiescent state, whereas at later stages hepatocytes 
divide to replace those destroyed by the host immune response and could allow HBx 
to manifest its deleterious activities. 
HBV HBV ∆XVect
 
Figure S11: HBx expressed from its own genome mediates cytotoxic activity 
 
HepG2 cells were cotransfected with replication competent wild-type HBV or HBV(∆HBx) genomic 
DNA and equal amounts of a GFP vector bearing a hygromycin resistance gene. Drug resistant cells 
were fixed and stained with crystal violet 20 days after transfection 
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 4.4.3 DDB1 is expressed in human liver  
 
Efficient HBV replication in the HepG2 cell line requires interaction between DDB1 
and HBx. Whether this interaction occurs during a natural HBV infection of the liver 
remains to be investigated. DDB1 is expressed in cells from a human liver biopsy and 
in freshly isolated human hepatocytes (Figure S12).   
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Figure S12: DDB1 is expressed in human liver 
 
Whole cell extracts were prepared from on hepatoma cells, a human liver biopsy and freshly isolated 
human hepatocytes. The proteins were separated by SDS-PAGE and analyzed by Western blotting for 
the presence of DDB1. This figure only reflects presence of DDB1 but is not quantitative (due to 
different exposure times except for both HepaRG lanes).  
 
This opens the possibility that the observed HBx interaction with DDB1 in cell 
culture may also occur in an infected liver and thereby contribute to efficient HBV 
replication and HCC development. Under normal conditions hepatocytes are mostly 
in a quiescent Go state and they divide infrequently. Proliferation is often greatly 
enhanced during chronic infection as a result of inflammation and regeneration, which 
could explain the appearance of undifferentiated cells during the infection. 
Preliminary data from the laboratory suggests that HBx-mediated toxicity require 
active cell division. To experimentally test this hypothesis, we will take advantage of 
the HepaRG cell line that was shown to support HBV infection [32]. This 
differentiated human hepatoma cell line can be induced to proliferation by removal of 
differentiation inducers (DMSO and Hydrocortisone) and therefore provide an ideal 
tool to assess whether HBx-mediated toxicity is cell proliferation-dependant. We 
found that DDB1 is expressed at comparable levels in dividing and non-dividing, 
differentiated HepaRG cells (Figure S12). Preliminary results from our collaborators 
in Lyon (D.Durantel, O.Hantz and F.Zoulim) suggest that proliferating HepaRG cells 
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transduced with a lentivirus encoding GFP-HBx exhibit altered morphology whereas 
the non-dividing differentiated cells show no morphological alterations. Further 
studies are currently in process and will allow to assess the possibility that the 
regeneration of the liver upon damage could provide an environment of proliferating 
hepatocytes favorable for HBx to induce cell cycle defects and thereby acting as a 
liver cancer cofactor.  
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4.5 Identification of protein interacting with DDB1 alone or with the 
HBx/DDB1 complex 
 
We obtained strong evidence that HBx does not act by preventing DDB1 from 
performing its normal functions, but that it is the HBx/DDB1 complex by itself that is 
toxic to the cells. This, together with the finding that HBx and DDB1 must interact 
through their natural binding regions to interfere with normal cell growth and to 
stimulate HBV replication, suggests that the HBx/DDB1 complex may function by 
providing a new surface for interaction with other cellular factors. Other members of 
the laboratory will perform a biochemical approach aimed at identifying higher order 
protein complexes containing HBx and DDB1. 
Since the laboratory has expertise in yeast genetics, we have set up a genetic screen 
related to the two-hybrid protein interaction assay that I will call yeast "two-plus-one" 
hybrid screen (schematized in Figure S13A). The screen is designed such as to allow 
selection of cDNA clones encoding VP16 activation domain-tagged proteins that 
require the presence of either the HBx/DDB1 complex or DDB1 alone to support 
yeast cell growth under selective conditions. The screen was performed in yeast strain 
carrying as a selectable marker gene an integrated copy of a his3 allele bearing a 
single RFX-binding site upstream of the TATA element. As bait we used DDB1 fused 
to the carboxyl-terminus of RFX (a human DNA binding protein). RFX-DDB1 was 
expressed from a centromeric plasmid marked with the URA3 gene whereas HBx was 
expressed in its native form from a centromeric plasmid marked with the ADE2 gene. 
Human cDNA libraries fused to VP16 were expressed under the control of galactose-
inducible Gal1,10 regulatory sequences from plasmids marked with the TRP1 gene. 
The RFX-DDB1 fusion was demonstrated to be suitable as bait since it has no 
transcriptional activity on its own and it was able to interact with a VP16-HBx fusion 
protein (data not shown). Additional test showed that a commercially available library 
fused to the Gal4 activation domain could also be used, since the RFX-DDB1 bait 
also interacted with a Gal4AD-HBx protein. After transformation of the library, 
colonies that show DDB1-dependent growth under selective conditions are identified 
as those that cannot loose the plasmid encoding RFX-DDB1. This has been done by 
replica-plating the colonies on medium containing 5-fluoroorotic acid (FOA), a drug 
that kills cells synthesizing the URA3 gene product. HBx-dependency was assessed by 
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the red phenotype due to accumulation of an intermediate in cells lacking a functional 
ADE2 gene and reflecting in these settings loss of the HBx-encoding plasmid. Library 
dependant growth was assessed by galactose induction of the VP16.cDNA. The 
cDNA clones from FOA-sensitive colonies that scored positive after rescue in E.coli 
and retransformation back into yeast were sequenced. 
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Figure S13: Interaction of DDB1 and the likely ortholog of mouse transient receptor 
4-associated protein (hTRP4-AP) in yeast 
 
A) Schematic diagram of the two-plus-one-hybrid assay. DDB1 fused carboxyl-terminally to the 
transcriptionally inactive human RFX-binding protein was used as bait in a screen for interaction with a 
cDNA library linked to the VP16 activation domain in presence of HBx expressed in its native form. 
B) VP16-hTRP4-AP was tested for interaction with RFX-DDB1 in the presence or absence of HBx 
(left panel) or SV5-V (right panel). The black bars represent the relative activities of an integrated lacZ 
reporter gene bearing a single RFX-binding site in strains expressing RFX-DDB1 alone (-) or together 
(+) with VP16-hTRP4-AP.  
 
Three independent transformations were performed with two VP16 activation 
domain-tagged human cDNA libraries. From several cDNA clones rescued in bacteria 
only 2 scored positive after retransformation into a yeast strain carrying an RFX-
dependant LacZ reporter gene integrated at the HIS3 locus. The 2 clones derived from 
2 different libraries correspond to the same mRNA encoding hTRP4-AP, the likely 
ortholog of mouse transient receptor protein 4 associated protein (NP_056453). The 
size of approximate 3,4 kb of the cDNA insert suggests the presence of the entire 
open reading frame. The yeast protein interaction assay showed that hTRP4-AP could 
bind to DDB1 in the presence of HBx (Figure S13B). However, HBx has almost no 
effect on the LacZ activity showing that HBx is not required for DDB1-hTRP4-AP 
interaction. Although HBx showed only a moderate interaction-promoting activity, 
we investigated if this interaction is compromised upon SV5-V overexpression as 
reported for the HBx-DDB1 interaction. Indeed, the LacZ activity dropped to 
background levels upon high levels of SV5-V expression. This reduction could reflect 
a mutually exclusive binding of SV5-V and hTRP4-AP to DDB1. However, since 
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HBx and hTRP4-AP appear to bind simultaneously to DDB1, these findings rather 
suggest that SV5-V induces a conformational change upon binding to DDB1 such that 
DDB1 can no longer bind to hTRP4-AP. An alternative explanation for these results 
is that SV5-V and hTRP4-AP bind to overlapping sites on DDB1, whereas hTRP4-AP 
and HBx do not. hTRP4-AP was named so because it interacts with transient receptor 
protein 4 in a yeast two-hybrid screen. Nothing is known about the receptor associated 
protein whereas the receptor itself was shown to be a calcium channel that can be 
activated by intracellular calcium store depletion. Calcium signaling by HBx has been 
shown to be important for HBV replication. A role for hTRP4-AP in the physiological 
functions of DDB1 or in the pathway, through which HBx acts to induce cell death 
and stimulation of viral replication, if any, remains to be demonstrated. For this 
purpose, biochemical (co-immunoprecipitation) and genetic (RNAi, overexpression) 
approaches will be used.  
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 5. Discussion 
 
5.1 Conclusion 
 
The HBV X protein (HBx) is essential for establishing natural viral infection and has 
been implicated in the development of liver cancer associated with chronic infection. 
HBx can interact with a number of unrelated cellular proteins and in cell culture it 
exhibits pleiotropic activities, including inhibition of cell growth and stimulation of 
HBV replication. HBx has been known for some time to interact with DDB1, the 
damaged DNA-binding protein 1 [58; 125], but the significance of this interaction has 
remained quite elusive. Here we show that both, inhibition of cell growth and 
stimulation of HBV replication, require the binding of HBx to DDB1. DDB1 is a 
protein originally described to form with DDB2 the UV-DDB complex that functions 
in DNA repair, and more recently found to assemble with cullin-4A and other proteins 
into complexes displaying E3 ligase activity.  
Our studies reveal several important aspects concerning the nature of the HBx-DDB1 
interaction and its functional importance for HBx-mediated activities. Among the 
many reported HBx-interacting proteins, DDB1 is the only for which an interaction 
with HBx has been documented independently by three labs. We found that the 
minimal region of HBx required for interaction with DDB1 resides between amino 
acids 76 and 125 [57], consistent with other reports identifying amino acids 55-101 
[176] or 66-101 [58] as critical for the interaction. Further structural analysis 
performed by C.Transy's group in Paris narrowed the interaction domain to amino 
acids 86 to 100 in WHx [181]. We identified two residues at position 96 and 98 as key 
determinants for HBx association with DDB1. Interestingly, these residues are strictly 
conserved in all mammalian hepadnaviruses. In our studies, the binding of HBx to 
DDB1 interferes with cell viability, by inducing lagging chromosomes and 
multinucleated cells, and promotes HBV genome replication. An HBx variant bearing 
a single substitution at either position 96 or 98 loses DDB1 binding and both 
concomitant activities. The nuclear fraction of HBx is responsible for both HBx-
mediated activities, acting predominantly on the amounts of viral mRNAs when tested 
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in viral replication studies. Several data provide evidence against HBx exerting its 
effect by simply sequestering DDB1 and thereby preventing its normal function. 
Indeed, overexpression of DDB1 does not relieve HBx toxicity [57] and a WHx 
mutant with increased DDB1-binding activity has been described that lacks cytotoxic 
properties [182]. Finally, fusion of a DDB1-binding defective HBx mutant to DDB1 
restores cytotoxic and replication-promoting activities to the otherwise inactive 
mutant suggesting that both proteins have to interact through their natural binding 
regions. We therefore believe that HBx may act by forcing DDB1 into its 
physiological function or by conferring new activities to the DDB1 protein. Overall, 
the stimulatory function of HBx on HBV replication depicts the same DDB1-
dependent binding properties than the previously reported HBx-mediated cytotoxic 
activity. Yet HBx-mediated cell death is not responsible for HBx-mediated 
stimulation of HBV replication, since the Huh7 hepatoma cell line shows HBx-
mediated cytotoxicity but no effect of HBx on HBV replication. Both HBx-mediated 
activities may involve distinct pathways at some point after the initial DDB1-HBx 
interaction.  
In support to our data, three properties that are functionally linked to the ability of X 
to engage a normal interaction with DDB1 have been reported; transactivation 
potential, proapoptotic effect and infectious potential of recombinant viruses in 
woodchuck [182; 183]. It is important to emphasize that the binding to DDB1 and the 
associated functions are conserved among the mammalian hepadnavirus X proteins 
[58]. To the best of our knowledge, this property has not been shown for other 
proposed cellular protein partners of the viral protein.  
 
The detailed comparison of SV5-V and HBx proteins in regard of DDB1 binding 
properties allowed us to unravel some aspects of the mechanisms governing HBx-
mediated cytotoxic activity. HBx, SV5-V (another viral partner) and DDB2 (the first 
described partner) all three compete for binding to DDB1. Consistent with a 
displacement of the DDB1-HBx interaction, ectopic DDB2 or SV5-V expression 
relieves HBx stabilization by DDB1 and blocks HBx-mediated interference with cell 
viability. The V protein of SV5 and HBx exhibit similar DDB1 binding properties, yet 
only HBx induces cell death. HBx performs a unique function through its association 
with DDB1 for which SV5-V cannot substitute.   
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This part of the work contributed several important findings. First pulse/chase 
experiments allowed us to show that the observed accumulation of the amount of viral 
proteins, upon cotransfection of DDB1, are determined by stabilization of the proteins 
through their interaction with DDB1 and not by transcriptional activity. Similarly, 
physical interaction between DDB1 and WHx has been reported to increase WHx 
stability by protecting it from proteasome-mediated degradation [181]. Second, we 
discovered that the binding of SV5-V to DDB1 serves for the degradation of STAT1. 
A finding that has been reported almost simultaneously by other groups [142; 175]. 
Both viral proteins have evolved to bind DDB1 to achieve distinct functions, both by 
a DDB2-independent mechanism. The finding that DDB1 is essential for STAT1 
degradation raises the possibility that HBx may interfere with cell viability through its 
binding to DDB1 by targeting important cellular control proteins for proteolysis. 
Unfortunately, the molecular targets of the HBx-DDB1 interaction could not yet be 
identified. 
 
The work on the relevance of the HBx-DDB1 interaction for proper HBV replication 
is particularly important because it represents the first evidence of a functional role of 
this interaction for the human hepatitis B virus. The manuscript in preparation not 
only shows that the stimulation of HBV replication correlates with the formation of 
the HBx-DDB1 complex but it also reveals by siRNA-mediated depletion that DDB1 
is essential for HBV replication. Evidence has been presented for a critical role of this 
interaction in efficient woodchuck hepatitis virus infection [183] arguing for a 
conserved role of the X-DDB1 complex in mammalian hepadnavirus replication. The 
interaction between HBx and DDB1 provides a potential target for the development of 
anti-hepatitis B virus drugs. Such drugs may provide a means to eliminate HBV in 
cases of chronic infection, thereby reducing the risk of developing liver cancer in the 
long term.  
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 5.2 Perspectives 
 
Further studies may address the following important issues: At which stage of the cell 
cycle and by which molecular mechanisms does HBx induce mitotic defects? What 
are the physiological functions of DDB1? What is the implication of Cullin-4A in the 
activities of DDB1? How does the HBx-DDB1 interaction act on viral replication? 
Can this interaction be observed in an HBV infected liver? 
 
Another challenge is to assess whether HBx exhibits cytotoxic activities only in 
actively dividing cells. Hepatocytes, which are the only confirmed site of replication 
of the HBV virus, divide infrequently under normal circumstances. However, 
proliferation is often enhanced during chronic infection as a result of liver 
regeneration upon host response. HBx has been suggested to activate the cyclinA 
promoter and could thereby promote cycling of growth-arrested cells into G1 [184]. 
Most probably for technical reasons, Séverine Bontron failed to provide evidence for 
the ability of HBx to induce cytotoxicity in dividing or non-dividing primary human 
immortalized hepatocytes (S.Bontron and T.Nguyen, personal communication). To 
further study this aspect, a collaboration with the HBV research group in Lyon 
(D.Durantel, O.Hantz and F.Zoulim) has been initiated.  The proliferation inducibility 
of the human differentiated hepatoma cell line HepaRG (see chapter 4.4.3) will be 
used to address the questions whether HBx induces the cell cycle in non-dividing cells 
and whether the interference with cell viability is cell division dependant. Preliminary 
data suggest that HBx-transduced proliferating HepaRG exhibit morphological 
alterations in a DDB1-binding dependant fashion whereas non-dividing cells seem to 
lack these defects (O.Hantz; personal communication).  
The alteration of the cell cycle progression induced by HBx acting in conjunction 
with DDB1 may be important in regard of the possible involvement of HBx in HCC 
development. Indeed, the mechanism by which HBx affects hepatocyte 
transformation is not clear. It is important to emphasize that HBx interferes with cell 
viability also when expressed at lower, most probably more physiological, levels from 
the viral genome under its own regulatory elements and in presence of the other viral 
proteins (Figure S11). Our data suggest that HBx induces centrosomal abnormalities 
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and aneuploidy, which are frequently found in many common cancers [113]. The 
multipolar divisions are expected to cause several chromosome missegregation and 
therefore constitute lethal events, but occasionally they might give rise to cells with 
chromosomal composition that enhance survival in the microenvironment of the 
tumor. Preliminary data from the laboratory show that HBx induces an extended S 
phase in a DDB1-binding dependant manner. Furthermore, the association of both 
DDB1 and HBx to chromatin at the G1/S boundary suggests a function for the HBx-
DDB1 complex at the level of replication initiation. Current studies try to assess the 
presence of one or both of the proteins at origins of replication.  
 
The different tools described in chapter 4.3 will be used to get further insights into the 
biology of DDB1 and to assess the implication of the cullin-4A E3 ubiquitin ligase in 
various DDB1 functions. The generation of cells lacking DDB1 by the RNA 
interference technique that can be complemented by a non-siRNA susceptible variant 
of DDB1 provides a system allowing to assess the function of DDB1 mutants on a 
null background. Since DDB1 is a large protein of 1140 amino acids that is 
particularly sensitive to deletions, a mutagenesis targeting specific residues will be 
privileged.  The imminent resolution of the crystal structure of DDB1 (N.Zheng, 
University of Washington, Seattle, personal communication) will greatly facilitate the 
targeting of surface exposed residues. The various DDB1 mutants could then be tested 
for: their interaction with HBx, SV5-V, DDB2 and CUL-4A; their ability to mediate 
any function required for HBx cytotoxic activity other than HBx-binding (assessed by 
fusion of DDB1 mutants to the wild-type HBx); their ability to support SV5-V 
mediated STAT-1 degradation; and finally their ability to restore normal cell growth 
of DDB1 depleted cells. 
The alterations in cell morphology observed upon long-term knockdown of 
endogenous DDB1 is consistent with the phenotype described for the deletion of the 
S.pombe orthologs [168; 169]. Recently, S.pombe DDB1 was shown to be implicated 
in cell cycle regulation by targeting for ubiquitin/proteasome-mediated degradation a 
protein involved in the control of the DNA replication checkpoint [167]. The presence 
of DDB1 in degradation complexes with E3 ubiquitin ligase activity argues in favor 
of a possible implication of cullin-4A, that possesses this ligase activity, in the 
different DDB1-dependant effects studied. Indeed inhibition of cullin-4A expression 
partially protects STAT-1 from degradation induced by the V protein of SV5 [142]. 
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Using the tools developed during this work, it should be possible to test whether 
cullin-4A is important for HBx activity. If cullin-4A is involved, we expect HBx to 
exhibit enhanced or reduced ability to affect cell viability and HBV replication under 
conditions of cullin-4A overexpression or silencing. The implication of cullin-4A in 
the alteration of cell cycle progression observed in DDB1-depleted cells will also be 
studied. 
The identification of putative proteins specifically interacting with the HBx/DDB1 
complex could allow us to further define the pathway involved in both HBx activities 
described in this work. However, one should keep in mind that HBx through its 
binding to DDB1 may act by targeting proteins for proteolysis, which therefore 
preclude us from isolating such interacting proteins in conditions where proteasomes 
are active. One would therefore prefer biochemical approaches in cells treated with 
proteasome inhibitors or as already initiated a two-plus-one hybrid screen in the yeast 
S.cerevisae in which the E3 ligase activity should be inactive due to the absence of a 
cullin-4A homologue.  
 
Finally to further strengthen the relevance of the DDB1-HBx interaction for efficient 
viral replication, studies assessing whether HBx and DDB1 do form a complex in 
infected liver will be performed. Our collaborators in Lyon have strong expertise in 
the study of the viral life cycle of the woodchuck virus and therefore possess a 
collection of infected liver samples. Co-immunoprecipitation studies using DDB1 or 
WHx specific antibodies should allow to address whether an interaction between 
these proteins could be observed in infected liver cells.  
The mechanisms whereby the interaction between HBx and DDB1 promotes viral 
replication will be further studied. DDB1 can function as a DNA-bound transcription 
factor [185], whereas HBx has reported single-stranded DNA and RNA binding 
activities [186]. This raises the possibility that HBx and DDB1 may exert their 
stimulatory effects by interacting with the viral DNA template and/or pgRNA. 
However, effects on the stability or export of the different viral RNA could also 
explain our results. Since HBx is widely recognised to have transcriptional activities, 
our observation that HBx similarly regulates the amounts of all detectable viral RNAs 
is more consistent with HBx stimulating transcription by binding to the viral DNA 
template. To examine this possibility, chromatin immunoprecipitation (ChIP) studies 
are under process. The approach consists of cross-linking proteins to DNA in vivo, 
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immunopurification of protein-DNA complexes using antibodies against the protein 
of interest and finally quantification of specific DNA fragments by polymerase chain 
reaction (PCR). The laboratory has established a highly quantitative ChIP assay by 
real-time PCR using a double-stranded DNA binding dye SYBR Green. The enhancer 
regions, especially Enh I are putative DDB1 or HBx binding regions on the viral 
DNA template. Another group rather reports that HBx stimulates HBV replication by 
enhancing the reverse transcription activity of the viral polymerase while having little 
effects on viral mRNA steady-state levels [119; 120]. It would be interesting to see in 
their cell growth conditions if HBx effect on the viral polymerase does also require its 
interaction with DDB1. 
 
 
In conclusion, the present thesis has contributed to our understanding of the 
mechanism and function of the DDB1-HBx interaction. In particular, it deepens 
studies on the HBx-mediated activity in cell culture but most importantly it reveals a 
role for this interaction in HBV genome replication. The results have opened 
interesting perspectives for anti-viral drug development. Furthermore, this work 
provides clues on the function of DDB1 in the cell. 
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6. Abbreviations 
 
 
   
AP-1   Activator protein 1 
cccDNA  covalently closed circular DNA 
CD   Cluster of differentiation 
cDNA   complementary DNA 
cEBP   CCAAT/enhancer binding protein 
CTL   Cytotoxic T lymphocytes 
DDB1   Damaged DNA-binding protein 1 
DDB2   Damaged DNA-binding protein 2 
DEN   Diethylnotrosamine 
DHBV   Duck hepatitis B virus 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DR   Direct repeats 
dsDNA  Double stranded DNA 
Enh   Enhancer 
FOA   5-fluoroortic acid 
HAV   Hepatitis A virus 
HBc   Hepatitis B viral core protein 
HBe   Hepatitis B viral early protein 
HBs   Hepatitis B viral surface protein 
HBV   Hepatitis B virus 
HBx   Hepatitis B viral X protein 
HCC   Hepatocellular carcinoma 
HCV   Hepatitis C virus 
HDV   Hepatitis delta virus  
HIV   Human immunodeficiency virus 
HNF-1   Hepatocyte nuclear factor 1 
hPIV2   Human parainfluenza virus 2 
HSP   Heat shock protein 
hTRP4-AP  Human transient receptor 4-associated protein 
IFN   Interferon 
ISRE   Interferon-stimulated response element 
JNK   Jun N-terminal kinase 
MAPK   Mitogen-activated protein kinase 
mRNA   Messenger RNA 
NES   Nuclear export signal 
NF-AT  Nuclear factor of activated T cells 
NF-kB   Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
NLS   Nuclear import signal 
nsi-DDB1  Non-siRNA susceptible DDB1 
ORF   Open reading frame 
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PCR   Polymerase chain reaction 
pgRNA  Pregenomic RNA 
PKC   Protein kinase C 
rcDNA  Relaxed circular DNA 
RFX   Regulatory factor X 
RNA   Ribonucleic acid 
RNase   Ribonuclease 
SAPK   Stress-activated protein kinase 
siRNA   small interfering RNA 
STAGA  SPT3/TAF9/GCN5 acetyltransferase complex 
STAT   Signal transducer and activator of transcription 
SV5-V   Simian virus 5 V protein 
TFIIB   Transcription factor II B 
TNF   Tumor necrosis factor 
uPA/RAG-2  Urokinase-type plasminogen (uPA)/recombinant activation gene-2 (RAG-2) 
UV-DDB  UV-damaged DNA-binding complex 
WHV   Woodchuck hepatitis virus 
WHx   Woodchuck hepatitis viral X protein 
WPRE   Woodchuck posttranscriptional regulatory element 
XP   Xeroderma pigmentosum 
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